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Foreword 
The role and impact of electronic cigarettes has been one of the great debates in public health 
in recent years and we commissioned this independent review of the latest evidence to ensure 
that practitioners, policy makers and, most importantly of all, the public have the best evidence 
available. 
 
Many people think the risks of e-cigarettes are the same as smoking tobacco and this report 
clarifies the truth of this. 
 
In a nutshell, best estimates show e-cigarettes are 95% less harmful to your health than 
normal cigarettes, and when supported by a smoking cessation service, help most smokers to 
quit tobacco altogether. 
 
We believe this review will prove a valuable resource, explaining the relative risks and benefits 
of e-cigarettes, in terms of harm reduction when compared with cigarettes and as an aid to 
quitting. 
 
We will continue to monitor the position and will add to the evidence base and guidance going 
forward. 
 
 
 
 
 
 
 
 
 
 
Duncan Selbie, Chief Executive, PHE 
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Key messages 
Key meages 
1. Smokers who have tried other methods of quitting without success could be 
encouraged to try e-cigarettes (EC) to stop smoking and stop smoking services 
should support smokers using EC to quit by offering them behavioural support. 
 
2. Encouraging smokers who cannot or do not want to stop smoking to switch to EC 
could help reduce smoking related disease, death and health inequalities. 
 
3. There is no evidence that EC are undermining the long-term decline in cigarette 
smoking among adults and youth, and may in fact be contributing to it. Despite 
some experimentation with EC among never smokers, EC are attracting very few 
people who have never smoked into regular EC use.  
 
4. Recent studies support the Cochrane Review findings that EC can help people to 
quit smoking and reduce their cigarette consumption. There is also evidence that 
EC can encourage quitting or cigarette consumption reduction even among those 
not intending to quit or rejecting other support. More research is needed in this 
area. 
 
5. When used as intended, EC pose no risk of nicotine poisoning to users, but e-
liquids should be in ‘childproof' packaging. The accuracy of nicotine content 
labelling currently raises no major concerns.  
 
6. There has been an overall shift towards the inaccurate perception of EC being as 
harmful as cigarettes over the last year in contrast to the current expert estimate 
that using EC is around 95% safer than smoking.  
 
7. Whilst protecting non-smoking children and ensuring the products on the market 
are as safe and effective as possible are clearly important goals, new regulations 
currently planned should also maximise the public health opportunities of EC.  
 
8. Continued vigilance and research in this area are needed. 
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Executive summary 
Following two previous reports produced for Public Health England (PHE) on e-
cigarettes (EC) in 2014, this report updates and expands on the evidence of the 
implications of EC for public health. It covers the EC policy framework, the prevalence 
of EC use, knowledge and attitudes towards EC, impact of EC use on smoking 
behaviour, as well as examining recent safety issues and nicotine content, emissions 
and delivery. Two literature reviews were carried out to update the evidence base since 
the 2014 reports and recent survey data from England were assessed. 
 
EC use battery power to heat an element to disperse a solution of propylene glycol or 
glycerine, water, flavouring and usually nicotine, resulting in an aerosol that can be 
inhaled by the user (commonly termed vapour). EC do not contain tobacco, do not 
create smoke and do not rely on combustion. There is substantial heterogeneity 
between different types of EC on the market (such as cigalikes and tank models). 
Acknowledging that the evidence base on overall and relative risks of EC in comparison 
with smoking was still developing, experts recently identified them as having around 4% 
of the relative harm of cigarettes overall (including social harm) and 5% of the harm to 
users. 
 
In England, EC first appeared on the market within the last 10 years and around 5% of 
the population report currently using them, the vast majority of these smokers or recent 
ex-smokers. Whilst there is some experimentation among never smokers, regular use 
among never smokers is rare. Cigarette smoking among youth and adults has 
continued to decline and there is no current evidence in England that EC are 
renormalising smoking or increasing smoking uptake. Instead, the evidence reviewed in 
this report point in the direction of an association between greater uptake of EC and 
reduced smoking, with emerging evidence that EC can be effective cessation and 
reduction aids.  
 
Regulations have changed little in England since the previous PHE reports with EC 
being currently governed by general product safety regulations which do not require 
products to be tested before being put on the market. However, advertising of EC is 
now governed by a voluntary agreement and measures are being introduced to protect 
children from accessing EC from retailers. Manufacturers can apply for a medicinal 
licence through the Medicines and Healthcare products Regulatory Agency (MHRA) and 
from 2016, any EC not licensed by the MHRA will be governed by the revised European 
Union Tobacco Products Directive (TPD).  
 
A summary of the main findings and policy implications from the data chapters now 
follows.  
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Summary of Chapter 3: UK policy framework 
The revised TPD will introduce new regulations for EC or refill containers which are not 
licensed by the MHRA. The cap on nicotine concentrations introduced by the TPD will 
take high nicotine EC and refill liquids off the market, potentially affecting heavier 
smokers seeking higher nicotine delivery products.  
  
The fact that no licensed EC are yet on the market suggests that the licensing route to 
market is not commercially attractive. The absence of non-tobacco industry products 
going through the MHRA licensing process suggests that the process is inadvertently 
favouring larger manufacturers including the tobacco industry, which is likely to inhibit 
innovation in the prescription market.  
 
Policy implications 
o From May 2016, following the introduction of the revised TPD, ECs will be more 
strictly regulated. As detailed elsewhere in the report, the information we present 
does not indicate widespread problems as a result of EC. Hence, the current 
regulatory structure appears broadly to have worked well although protecting non-
smoking children and ensuring the products on the market are as safe and effective 
as possible are clearly important goals. New regulations currently planned should 
be implemented to maximise the benefits of EC whilst minimising these risks. 
 
o An assessment of the impact of the TPD regulations on the UK EC market will be 
integral to its implementation. This should include the degree to which the 
availability of safe and effective products might be restricted.  
 
o Much of England’s strategy of tobacco harm reduction is predicated on the 
availability of medicinally licensed products that smokers want to use. Licensed ECs 
are yet to appear. A review of the MHRA EC licensing process therefore seems 
appropriate, including manufacturers’ costs, and potential impact. This could include 
a requirement for MHRA to adapt the processes and their costs to enable smaller 
manufacturers to apply, and to speed up the licensing process. The review could 
also assess potential demand for the EC prescription market and what types of 
products would be most appropriate to meet that demand. 
 
Summary of Chapter 4: Prevalence of e-cigarette use in England/Great Britain 
Adults: Around one in 20 adults in England (and Great Britain) use EC. Current EC 
users are almost exclusively smokers (~60%) or ex-smokers (~40%), that is smokers 
who now use EC and have stopped smoking altogether. EC use among long-term ex-
smokers is considerably lower than among recent ex-smokers. Current EC use among 
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never smokers is very low, estimated to be 0.2%. The prevalence of EC use plateaued 
between 2013-14, but appeared to be increasing again in 2015.  
 
Youth: Regular EC use among youth is rare with around 2% using at least monthly and 
0.5% weekly. EC use among young people remains lower than among adults: a minority 
of British youth report having tried EC (~13%). Whilst there was some experimentation 
with EC among never smoking youth, prevalence of use (at least monthly) among never 
smokers is 0.3% or less.  
 
Overall, the adult and youth data suggest that, despite some experimentation with EC 
among never smokers, EC are attracting few people who have never smoked into 
regular use.  
 
Trends in EC use and smoking: Since EC were introduced to the market, cigarette 
smoking among adults and youth has declined. In adults, overall nicotine use has also 
declined (not assessed for youth). These findings, to date, suggest that the advent of 
EC is not undermining, and may even be contributing to, the long-term decline in 
cigarette smoking.  
 
Policy implications 
o Trends in EC use among youth and adults should continue to be monitored using 
standardised definitions of use. 
 
o Given that around two-thirds of EC users also smoke, data are needed on the 
natural trajectory of ‘dual use’, ie whether dual use is more likely to lead to smoking 
cessation later or to sustain smoking (see also Chapter 6). 
 
o As per existing NICE guidance, all smokers should be supported to stop smoking 
completely, including ‘dual users’ who smoke and use EC.  
 
Summary of Chapter 5: Smoking, e-cigarettes and inequalities 
Smoking is increasingly concentrated in disadvantaged groups who tend to be more 
dependent. EC potentially offer a wide reach, low-cost intervention to reduce smoking 
and improve health in disadvantaged groups.  
 
Some health trusts and prisons have banned the use of EC which may 
disproportionately affect more disadvantaged smokers.  
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Policy implications 
o Consideration could be given to a proactive strategy to encourage disadvantaged 
smokers to quit smoking as quickly as possible including the use of EC, where 
appropriate, to help reduce health inequalities caused by smoking. 
 
o EC should not routinely be treated in the same way as smoking. It is not appropriate 
to prohibit EC use in health trusts and prisons as part of smokefree policies unless 
there is a strong rationale to do so.  
 
Summary of Chapter 6: E-cigarettes and smoking behaviour 
Recent studies support the Cochrane Review findings that EC can help people to quit 
smoking and reduce their cigarette consumption. There is also evidence that EC can 
encourage quitting or cigarette consumption reduction even among those not intending 
to quit or rejecting other support. It is not known whether current EC products are more 
or less effective than licensed stop smoking medications, but they are much more 
popular, thereby providing an opportunity to expand the number of smokers stopping 
successfully. Some English stop smoking services and practitioners support the use of 
EC in quit attempts and provide behavioural support for EC users trying to quit smoking; 
self-reported quit rates are at least comparable to other treatments.  The evidence on 
EC used alongside smoking on subsequent quitting of smoking is mixed.  
 
Policy implications 
o Smokers who have tried other methods of quitting without success could be 
encouraged to try EC to stop smoking and stop smoking services should support 
smokers using EC to quit by offering them behavioural support.  
 
o Research should be commissioned in this area including: 
 longitudinal research on the use of EC, including smokers who have not used 
EC at the beginning of the study 
 the effects of using EC while smoking (temporary abstinence, cutting down) on 
quitting, and the effects of EC use among ex-smokers on relapse 
 research to clarify the factors that i) help smokers using EC to quit smoking and 
ii) deter smokers using EC from quitting smoking, including different EC 
products/types and frequency of use and the addition of behavioural support, 
and how EC compare with other methods of quitting which have a strong 
evidence base 
  
o It would be helpful if emerging evidence on EC (including different types of EC) and 
how to use EC safely and effectively could be communicated to users and health 
professionals to maximise chances of successfully quitting smoking.  
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Summary of Chapter 7: Reasons for use and discontinuation 
A number of surveys in different populations provide evidence that reducing the harm 
from smoking (such as through cutting down on their cigarette consumption or helping 
with withdrawal during temporary abstinence) and the desire to quit smoking cigarettes 
are the most important reasons for using EC. Curiosity appears to play a major role in 
experimentation. Most trial of EC does not lead to regular use and while there is less 
evidence on why trial does not become regular use, it appears that trial due to curiosity 
is less likely to lead to regular use than trial for reasons such as stopping smoking or 
reducing harm. Dissatisfaction with products and safety concerns may deter continued 
EC use.  
 
Policy implications 
o Smokers frequently state that they are using EC to give up smoking. They should 
therefore be provided with advice and support to encourage them to quit smoking 
completely. 
 
o Other reasons for use include reducing the harm from smoking and such efforts 
should be supported but with a long-term goal of stopping smoking completely.  
 
Summary of Chapter 8: Harm perceptions 
Although the majority of adults and youth still correctly perceive EC to be less harmful 
than tobacco cigarettes, there has been an overall shift towards the inaccurate 
perception of EC being at least as harmful as cigarettes over the last year, for both 
groups. Intriguingly, there is also some evidence that people believe EC to be less 
harmful than medicinal nicotine replacement therapy (NRT). 
 
Policy implications  
o Clear and accurate information on relative harm of nicotine, EC and tobacco 
cigarettes is needed urgently (see also Chapter 10). 
 
o Research is needed to explore how health perceptions of EC are developed, in 
relation to tobacco cigarettes and NRT, and how they can be influenced.  
 
Summary of Chapter 9: E-cigarettes, nicotine content and delivery 
The accuracy of labelling of nicotine content currently raises no major concerns. Poorly 
labelled e-liquid and e-cartridges mostly contained less nicotine than declared. EC used 
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as intended pose no risk of nicotine poisoning to users. However, e-liquids should be in 
‘childproof’ packaging. 
 
Duration and frequency of puffs and mechanical characteristics of EC play a major role 
in determining nicotine content in vapour. Across the middle range of nicotine levels, in 
machine tests using a standard puffing schedule, nicotine content of e-liquid is related 
to nicotine content in vapour only weakly. EC use releases negligible levels of nicotine 
into ambient air with no identified health risks to bystanders. Use of a cigalike EC can 
increase blood nicotine levels by around 5 ng/ml within five minutes of use. This is 
comparable to delivery from oral NRT. Experienced EC users using the tank EC can 
achieve much higher blood nicotine levels over a longer duration, similar to those 
associated with smoking. The speed of nicotine absorption is generally slower than from 
cigarettes but faster than from NRT. 
 
Policy implications  
o General labelling of the strength of e-liquids, along the lines used for example 
indicating coffee strength, provides sufficient guidance to consumers.  
 
o Regulatory interventions should ensure optimal product safety but make sure EC 
are not regulated more strictly than cigarettes and can continue to evolve and 
improve their competitiveness against cigarettes.   
 
Summary of Chapter 10: Safety of e-cigarettes in light of new evidence 
Two recent worldwide media headlines asserted that EC use is dangerous. These were 
based on misinterpreted research findings. A high level of formaldehyde was found 
when e-liquid was over-heated to levels unpalatable to EC users, but there is no 
indication that EC users are exposed to dangerous levels of aldehydes; stressed mice 
poisoned with very high levels of nicotine twice daily for two weeks were more likely to 
lose weight and die when exposed to bacteria and viruses, but this has no relevance for 
human EC users. The ongoing negative media campaigns are a plausible explanation 
for the change in the perception of EC safety (see Chapter 8).  
 
None of the studies reviewed above alter the conclusion of Professor Britton’s 2014 
review for PHE. While vaping may not be 100% safe, most of the chemicals causing 
smoking-related disease are absent and the chemicals which are present pose limited 
danger. It has been previously estimated that EC are around 95% safer than smoking. 
This appears to remain a reasonable estimate.  
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Policy implications 
o There is a need to publicise the current best estimate that using EC is around 95% 
safer than smoking. 
 
o Encouraging smokers who cannot or do not want to stop smoking to switch to EC 
could be adopted as one of the key strategies to reduce smoking related disease 
and death. 
 
Summary of Chapter 11: Other health and safety concerns 
There is a risk of fire from the electrical elements of EC and a risk of poisoning from 
ingestion of e-liquids. These risks appear to be comparable to similar electrical goods 
and potentially poisonous household substances.  
 
Policy implications 
o The risks from fire or poisoning could be controlled through standard regulations 
for similar types of products, such as childproof containers (contained within the 
TPD but which are now emerging as an industry standard) and instructions about 
the importance of using the correct charger. 
 
o Current products should comply with current British Standard operating standards. 
 
o Records of EC incidents could be systematically recorded by fire services. 
 
Summary of Chapter 12: International perspectives 
Although EC use may be lower in countries with more restrictions, these restrictions 
have not prevented EC use. Overall, use is highest among current smokers, with low 
numbers of non-smokers reporting ever use. Current use of EC in other countries is 
associated with being a smoker or ex-smoker, similar to the findings in the UK. EC use 
is frequently misreported with experimentation presented as regular use. Increases in 
youth EC trial and use are associated with decreases in smoking prevalence in all 
countries, with the exception of one study from Poland. 
 
Policy implications 
o Future research should continue to monitor and evaluate whether different EC 
policies across countries are related to EC use and to smoking cessation and 
smoking prevalence. 
 
o Consistent and agreed measures of trial, occasional and regular EC use among 
youth and adults are urgently needed to aid comparability. 
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1. Introduction  
Despite the decline in smoking prevalence observed over the last few decades, there 
remain over eight million smokers in England. Most of these are from manual and more 
disadvantaged groups in society, including those with mental health problems, on low 
income, the unemployed and offenders. In some such population groups, the proportion 
who smoke is over two or three times higher than that in the general population, a level 
of smoking observed in the general population over 40 years ago. For those who 
continue to smoke regularly, much of their lives will be of lower quality and spent in 
poorer health than those who don’t smoke, and they will have a one in two chance of 
dying prematurely, by an average of 10 years, as a direct result of their smoking. 
Smoking is therefore the largest single contributor to health inequalities as well as 
remaining the largest single cause of preventable mortality and morbidity in England. 
 
Moving forward, it is therefore important to maintain and enhance England’s 
comprehensive tobacco control strategy in order to motivate and support all smokers in 
society to stop smoking as quickly as possible, and prevent the recruitment of new 
smokers. Harm reduction guidance, published by the National Institute for Health and 
Care Excellence in England in 2013,  recognised that some smokers struggled to quit 
abruptly and that cigarettes were a lethal delivery system for nicotine [1]; it is widely 
accepted that most smokers smoke for the nicotine but die from the other smoke 
constituents. Harm reduction has been identified as one of the more promising policy 
options to reduce smoking induced inequalities in health [2]. All experts agree that a 
well-resourced comprehensive strategy, involving cessation, prevention and harm 
reduction should make the goal of a smoke-free society in England quickly achievable. 
 
However, the advent of electronic cigarettes (EC) over recent years has caused 
controversy. In 1991, Professor Michael Russell, a leading English smoking cessation 
expert from the Institute of Psychiatry, argued that ”it was not so much the efficacy of 
new nicotine delivery systems as temporary aids to cessation, but their potential as 
long-term alternatives to tobacco that makes the virtual elimination of tobacco a realistic 
future target”, and he recommended that “tobacco should be rapidly replaced by 
cleaner, less harmful, sources of nicotine” [3]. Professor Russell was one of the first to 
recognise the critical role that nicotine played in tobacco use and he identified that 
whilst there were good ethical and moral reasons not to promote nicotine addiction in 
society, the harm caused by nicotine was orders of magnitude lower than the harms 
caused by cigarette smoke. Professor Russell was also a pioneer of new treatments for 
smoking cessation, in particular, nicotine replacement therapies (NRT). Since then, the 
number of NRT products has proliferated such that there are now several different 
delivery routes and modes and countless different dosages and flavours. However, 
even with a relaxation of the licensing restrictions which increased their accessibility, 
NRT products have never become popular as an alternative to smoking.  
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In 2004, the first EC was marketed in China, and EC started to appear in England in 
2006/7. The subsequent three years saw a rapid rise in their use. Whilst Professor 
Russell died in 2009, predating the arrival of these products in England, proponents of 
EC similarly recognised their potential to contribute towards making a smoke-free 
society more rapidly achievable [4]. Those against EC, however, believed that they 
were at best a distraction, at worst a means of undoing decades of progress in reducing 
smoking [5]. 
 
Any new tobacco control strategy for England must therefore incorporate a nicotine 
strategy, which should include recommendations and an appropriate regulatory 
framework for EC. This report attempts to inform that strategy by reviewing recent 
evidence and surveys relating to the use of EC and how they impact smoking 
behaviour. The focus is England, although we also draw on evidence from elsewhere 
in the UK and internationally.      
 
Description of e-cigarettes 
EC use battery power to heat an element to disperse a solution that usually contains 
nicotine. The dispersion of the solution leads to the creation of an aerosol that can be 
inhaled by the user. The heated solution typically contains propylene glycol or glycerine, 
water, nicotine, and flavourings. EC do not contain tobacco, do not create smoke and 
do not rely on combustion. Whilst EC ‘smoke’ is technically an aerosol, throughout this 
report we use the established terminology of vapour, vaping and vaper.  
 
There is substantial heterogeneity between different types of EC and the speed with 
which they are evolving making them difficult to categorise. ECs available in England 
can be classified into three basic types: (1) EC that are either (a) disposable or (b) use 
pre-filled cartridges that need to be replaced once emptied. We will refer to these using 
their most common name, ‘cigalikes’. Most cigalikes resemble cigarettes, although it is 
important to note that some do not; (2) EC that are designed to be refilled with liquid by 
the user. We will refer to these using their common name ‘tank systems’. (3) Finally, 
some EC products, mostly tank systems that allow users to regulate the power delivery 
from the batteries to the atomizer. These we refer to as mods or ‘variable power EC’.  
 
In the UK, the most prominent brands of cigalikes are now owned by the tobacco 
industry. To the authors’ knowledge only one tobacco company sells a tank model in the 
UK, with the rest of the market consisting of non-tobacco industry companies. Some 
products have also been introduced by the tobacco industry that could be referred to as 
‘hybrids’ such that they use pre-filled nicotine cartridges but look like tank models. 
Additionally, a few EC that are similar to cigalikes in function are also sold that use 
cartridges that can be refilled, and some users will puncture holes/remove the ends of 
cigalike cartridges to refill them instead of buying new cartridges. 
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Studies have validated the ability of EC to deliver nicotine to the user. Blood plasma 
nicotine concentrations increase after inhalation of EC aerosol [6, 7], and cotinine, a 
biomarker for nicotine, has been detected in the saliva of EC users [8, 9]. Information 
about the overall and relative risks of EC in comparison with smoking has also been 
developing. Using a multi-criteria decision analysis (MCDA) model, the Independent 
Scientific Committee on Drugs selected experts from several different countries to 
compare a variety of nicotine products on variables of harm identified by the UK 
Advisory Council on the Misuse of Drugs [10]. EC were identified as having 4% of the 
relative harm of cigarettes overall (including social harm) and 5% of the harm to users, 
although it was acknowledged that there was a lack of hard evidence for the harms of 
most of the nicotine products on most of the criteria.  
 
Structure of report 
Following Chapter 2 on methodology, Chapter 3 assesses the current and future policy 
framework for EC. Chapters 4 and 5 assess trial and usage in England among adults 
and youth as well as different socioeconomic groups where evidence permits. Chapter 6 
examines the evidence for the impact of EC on smoking behaviour including the use of 
EC in quit attempts as well as alongside smoking. Chapter 7 assesses reasons for 
trying and discontinuing EC and Chapter 8 perceptions of relative harms of EC and 
smoking. Chapter 9 discusses nicotine content and emissions of EC as well as nicotine 
uptake in users. Chapters 10 and 11 assess different aspects of safety drawing on 
recent published studies as well as national statistics. Chapter 12 examines 
international perspectives of EC policies and usage.  
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2. Methodology 
For the present report we have included: (1) a synthesis of recent evidence (published 
since the two PHE 2014 EC reports) with the earlier evidence in the earlier PHE reports 
drawing on both national and international literature; and  (2) where feasible, an 
analysis of any relevant national unpublished data available to PHE, KCL and partner 
organisations from England, Great Britain or the UK, including: i) Smoking Toolkit Study 
(UCL); ii) Action on Smoking and Health (ASH) Smokefree GB (adult and youth) 
surveys; iii) Internet Cohort GB survey; iv) Smokers’ surveys 2014 commissioned by 
ASH from YouGov; and v) the International Tobacco Control (ITC) policy evaluation 
project.   
 
For the evidence review (1) above, given the short timeframe for this report, a 
systematic review of the literature was not possible. However, we followed systematic 
review methods where possible and searched PubMed for studies from 2014 onwards 
using the following search terms:  (("2014/01/01"[Date - Publication] : "3000"[Date - 
Publication])) AND ((((((((e-cigarette) OR Electronic cigarettes) OR e-cig*) OR electronic 
cig*) OR ENDS) OR electronic nicotine delivery systems) OR electronic nicotine 
delivery system) OR ((Nicotine) AND Vap*)).  
 
The term ENDS was used as some studies have referred to e-cigarettes as Electronic 
Nicotine Delivery Systems (ENDS). This search returned 3,452 records. The titles of all 
records were screened and 798 articles were identified as potentially relevant to the 
report. The full papers of abstracts considered relevant by two reviewers were retrieved 
and reviewed as identified in Appendix A.   
 
We wanted to ensure we included the most up-to-date information on EC use and 
impact in England. In order to do this we used routine national data sources to retrieve 
measures of EC use prevalence, fires, poisoning and other adverse events. Specifically 
for (2) above, we assessed, in addition to published papers, unpublished national 
survey data relevant to this work, identifying where findings are peer 
reviewed/published. The methods of the surveys that we have accessed are as follows: 
 
Smoking Toolkit Study (STS, University College London) 
The STS consists of monthly cross-sectional household interviews of adults (aged 
16 and over) in England that has been running since November 2006. Each month 
involves a new nationally representative sample of about 1,800 respondents. Since 
2009, all respondents who smoked in the last year have been asked questions on EC; 
since November 2013 all respondents complete questions on EC. For more information, 
see www.smokinginengland.info  
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ASH Smokefree GB (adult and youth) surveys  
Adult: ASH has conducted cross-sectional internet surveys of adults (aged 18 and 
over) in Great Britain (GB) since 2007. These surveys cover a wide range of tobacco 
control policies and smoking behaviour and are carried out on ~12,000 adults each 
year. Questions on EC were included first in 2010, with new EC questions added in 
each subsequent survey (2012, 2013, 2014, 2015).   
 
Youth: ASH has conducted cross-sectional surveys of British youth (aged 11-18) 
three times to date (2013, 2014, 2015). Younger participants are recruited, online, 
through the adult YouGov participants with older participants contacted directly. It has 
been used to give a more contemporaneous and comprehensive snapshot of youth 
attitudes towards smoking and their behaviours (and includes a breakdown of trial and 
more prolonged use of EC) than UK Government national surveys have been able to.  
 
Internet Cohort GB survey (King’s College London, University College London) 
A unique longitudinal internet survey of smokers and recent ex-smokers in GB (aged 16 
and over) surveyed first in 2012 and then again in December 2013 and 2014. Of the 
5,000 respondents in the initial sample, 1,031 respondents (20.7%) used EC at all at the 
time of the survey in 2012. The prevalence of past-year smoking in this baseline sample 
was similar to that identified through the STS (which, as stated above, recruited 
representative samples of the population in England), over a comparable period. 
 
In 2013, 2,182 of the 5,000 were followed up and in 2014, 1,519 were followed up. EC 
use was 32.8% (n=717) in 2013 and 33.2% (n=505) in 2014. The study sample was 
recruited from an online panel managed by Ipsos MORI who were invited by email to 
participate in an online study and were screened for smoking status. The survey 
included questions on smoking and quitting behaviour and stress and general health as 
well as detailed questions on EC usage. 
 
ASH GB Smokers’ survey 2014  
This is an online survey carried out by YouGov for ASH specifically to assess more 
detailed attitudinal measures concerning nicotine containing products. The 2014 survey 
involved 1,203 adult smokers and recent ex-smokers selected from the ASH Smokefree 
adult survey to have roughly equal numbers of smokers who had (n=510) and had not 
(n=470) tried EC and a smaller number of ex-smokers who had tried EC (n=223).  
 
ITC Policy Evaluation project  
A longitudinal cohort survey of smokers and recent ex-smokers (aged 18 and over), 
surveyed by telephone and internet. The ITC UK survey started in 2002 and surveys 
E-cigarettes: an evidence update 
 
19 
have been conducted approximately annually since that time. Probability sampling 
methods are utilised through telephone surveys using random digit dialling, but in more 
recent survey waves participants could opt to complete surveys on the internet. The ITC 
UK study benefits from parallel cohort surveys in Australia, Canada and the United 
States, enabling comparisons across countries with different tobacco and EC policies. 
Each wave of the survey includes approximately 1,500 UK respondents. EC questions 
were added to the last three waves. Data from the last wave (in 2014) were not 
available for inclusion in this report, but published papers from earlier waves are 
included. More details of the methodology are available at www.itcproject.org  
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3. UK policy framework 
E-cigarette regulations in England: current and proposed 
Regulations have changed little in England since the previous PHE reports. Currently 
EC are governed by general product safety regulations (UK and EU) which do not 
require that the products be tested before being put on the market. However, 
manufacturers can apply for a medicinal licence through the Medicines and Healthcare 
products Regulatory Agency (MHRA) [11] and from next year any EC not licensed by 
the MHRA will be governed by the revised European Union Tobacco Products Directive 
(TPD)[12]. Both the MHRA licensing and the TPD regulatory routes are described 
below. The TPD regulations are extensive and will have a significant impact on the EC 
market.  
 
One change from the previous PHE report, which was introduced by the Advertising 
Standards Authority in October 2014, is that until the TPD comes into force, advertising 
of EC is governed by a voluntary agreement. This agreement indicates, inter alia, that 
advertising must be socially responsible, not promote any design, imagery or logo that 
might be associated with a tobacco brand or show the use of a tobacco product in a 
positive light, make clear that the product is an EC and not a tobacco product, not 
undermine quit tobacco messaging, and must not contain health or medicinal claims 
unless the product is licensed. These guidelines will be reviewed in October 2015 and 
when more is known about the application of the TPD the role of the Code will be 
clarified. 
 
A further recent change is the introduction of measures to protect children from EC: an 
age of sale lower limit of 18 years of age (in line with tobacco cigarettes) is being 
introduced and a ban on proxy purchasing of EC.  
 
EU Tobacco Products Directive (TPD) route 
The revised TPD will introduce new regulations for EC or refill containers (referred to 
below as products) which are not licensed by the MHRA. We have listed these in detail 
below because they are wide-ranging and will impose a significant step change for 
manufacturers, importers and Member State (MS) authorities:  
 
 notification: Manufacturers must inform competent authorities of the MS six months 
before placing new products on the market. For those already on the market by 20 
May 2016, the notification needs to be submitted within six months of this date. Each 
substantial modification of the product requires a new notification 
 reporting obligations (for which manufacturers/importers might be charged) 
include: 
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 details (including quantification) on all the ingredients contained in, and 
emissions resulting from the use of, the product, by brand name 
 toxicological data regarding ingredients and emissions, including when heated, 
with reference particularly to health of consumers when inhaled including any 
addictive effect 
 information on nicotine doses and uptake when consumed under normal or 
reasonably foreseeable conditions 
 description of the product components, including where appropriate opening 
and refill mechanisms of product or refill containers 
 description of the production process and declaration that it conforms with the 
TPD 
 declaration that manufacturer/importer bear full responsibility for the quality and 
safety of the product when placed on market and used under normal or 
reasonably foreseeable conditions 
 nicotine-containing liquid restrictions:  
 EC must not contain more than 20 mg/ml of nicotine  
 nicotine-containing liquid must be in dedicated refill containers not exceeding 
10ml volume, and cartridges or tanks do not exceed a volume of 2ml 
 additives are not prohibited but the nicotine-containing liquids cannot contain 
additives that are otherwise prohibited by the other Articles in the TPD 
 high purity ingredients must be used and substances other than those declared 
should only be present in trace quantities which are unavoidable during 
manufacture  
 ingredients must not pose a risk to health either when heated or not heated 
 nicotine doses must be delivered at consistent levels under normal conditions of 
use 
 products are required to be child and tamper proof, protected against breakage and 
leakage and have a mechanism that ensures refilling without leakage 
 products must include a leaflet with information on: 
 instructions for use and storage of the product, including a reference that the 
product is not recommended for use by young people and non-smokers 
 contra-indications 
 warnings for specific groups 
 possible adverse effects 
 addictiveness and toxicity 
 contact details of manufacturer/importer and a legal or natural contact person 
within the EU 
 outside packaging of products must include: 
 list of all ingredients contained in the product in descending order of the weight 
 an indication of the nicotine content and delivery per dose 
 batch number 
 recommendation to keep the product out of reach of children 
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 no promotional element or feature or such that suggests the product is harm 
reducing  (or other features described in Article 13 of the Directive) 
 health warnings: 
 One of the following must be shown: 
 ‘This product contains nicotine which is a highly addictive substance. It is 
not recommended for use by non-smokers’ or 
 ‘This product contains nicotine which is a highly addictive substance’  
 Member States shall determine which health warning to use 
 health warnings must comply with regulations concerning specific provisions on 
position and size  
 cross-border advertising and promotion, sponsorship etc of products will be 
prohibited (unless trade information) 
 cross-border sales of products may be prohibited or subject to a registration 
scheme 
 manufacturers/importers of products to submit an annual submission on their 
products to competent authorities in MS which should include: 
 comprehensive data on sales volumes, by brand name and product type 
 information on preferences of various consumer groups, including young 
people, non-smokers and the main types of current users 
 mode of sale of the products 
 executive summaries of any market surveys carried out in respect of the above, 
including an English translation thereof products 
 MS shall monitor the market developments concerning products, including any 
evidence that their use is a gateway to nicotine addiction and ultimately traditional 
tobacco consumption among young people and non-smokers. This information to be 
made publicly available on a website although the need to protect trade secrets 
should be taken into account 
 MS should on request, make all information relevant to this Article available to the 
Commission and other Member States who will respect confidential information 
 MS shall require manufacturers, importers and distributors of products to establish 
and maintain a system for collecting information about all of the suspected adverse 
effects on human health  
 corrective action should be taken immediately if economic operators consider or 
have reason to believe that products are not safe or of good quality or not 
conforming to the Directive, ensuring conformity or withdrawal or recall from the 
market. In such cases, operators are required to inform immediately market 
surveillance authorities of the MS giving details of risk to human health and safety, 
corrective action taken and results of such corrective action. MS may request 
additional information from the economic operators on safety and quality aspects or 
any adverse effect of products  
 the Commission will submit a report to the European Parliament and the Council on 
potential risks to public health by 20 May 2016 and as appropriate thereafter 
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 where a competent authority believes specific products could pose a serious risk to 
human health it should take appropriate provisional measures, immediately inform 
Commission and competent authorities of other MS of measures taken and 
communicate any supporting data. The Commission will determine whether 
provisional measure is justified informing the MS concerned of its conclusions to 
enable appropriate follow-up measures to be taken 
 the Commission can extend any prohibition to other MS if such an extension is 
justified and proportionate 
 the Commission is empowered to adapt wording of health warnings and ensure 
factual 
 the Commission will give a common format for notification and technical standard for 
the refill mechanism outlined above 
 
The exact date of implementation in England is yet to be specified but full compliance is 
likely to be necessary by 2017. One UK company, Totally Wicked, has challenged the 
UK’s intention to transpose the Directive into UK law. The case rests on whether the 
TPD was properly made and has been referred to the European Court of Justice for a 
preliminary ruling. This is expected in late 2015/early 2016.  
 
During implementation, government will need to undertake an impact assessment for 
the UK market on the final proposals as set out in the Directive and this will be 
consulted upon. The TPD certainly raises the barrier for bringing EC products to market 
or continuing to market existing products, and will undoubtedly constrain the EC market. 
Understanding any unintended consequences of the EU TPD as well as intended ones 
will be important. For example, the cap on nicotine concentrations introduced by the 
TPD will take high nicotine EC and refill liquids off the market, potentially affecting 
heavier smokers seeking higher nicotine delivery products. 
 
Medicines and Healthcare products Regulatory Agency (MHRA) licensing route 
Following a consultation in 2010, the UK MHRA introduced a mechanism for the 
licensing of EC and other nicotine containing products as medicines requiring medicinal 
purity and delivery standards. Such a licence would be required for products to be 
prescribed on the NHS. As with other licensed nicotine containing products, advertising 
controls would be applied and VAT of 5% would be imposed. 
 
The licensing process has been described by the MHRA [11]. This regulation was 
described initially as ‘light touch’ recognising a product that delivered nicotine could be 
effectively used for harm reduction or cessation purposes, thus implying a relatively 
speedy route to licensing. This was subsequently changed to ‘right touch’ as it was 
apparent that the process was more lengthy and costly than originally envisaged. We 
understand that the MHRA estimated costs for a one-off application of between £252K 
and £390K with an annually recurring cost of between £65K and £249K, for each 
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product. This does not include the costs of making manufacturing facilities and products 
MHRA compliant – estimated at several million pounds. 
 
At the time of writing one non-EC nicotine inhaler product, Voke, developed by Kind 
Consumer, and to be marketed by British American Tobacco (BAT), had received a 
medicinal licence, although it is not yet being marketed in England. A further BAT 
product (an EC) is currently going through the application process. Other EC products 
are currently in the pipeline with the MHRA but it is not clear at what stage the 
applications are or what types of products, eg cigalikes or tank models, are involved.  
 
The absence of a licensed product, five years after the MHRA’s consultation took place, 
suggests that this route to market is not commercially attractive. The fact that the only 
product at the application stage is a BAT product suggests that the process is very 
resource intensive. As well as cost, other possible reasons include complexity, a lack of 
desire to engage with medicinal licensing or the MHRA, the entrepreneurial nature of 
the EC manufacturers and a possible lack of perceived benefits to acquiring a licence. 
This could be problematic when the EU TPD is implemented, which is likely to constrain 
the over-the-counter market. Additionally, having a diverse range of EC on prescription 
is likely to be beneficial (similar to nicotine replacement tobacco (NRT) products – when 
new products are introduced, evidence suggests that they do not cannibalise the 
existing NRT product market but instead expand the use of medications). This means 
that small manufacturers, particularly non-tobacco industry manufacturers, who may be 
producing a greater variety or more satisfying EC, will not compete with larger 
corporations such as the tobacco industry in the prescriptions market. There are several 
consequences of this which should be explored. These could include an inhibition of 
innovation and damage public health. Alternatively, given the demand for prescribed EC 
products is as yet unknown, particularly in the population groups where smoking 
prevalence is elevated, the medicinal route may not impact public health. The appeal of 
EC may rest in the fact that they are not medicines. A review of the MHRA licensing 
process for EC, and its likely impact, is recommended.  
 
Summary of findings 
The revised TPD will introduce new regulations for EC or refill containers which are not 
licensed by the MHRA. The cap on nicotine concentrations introduced by the TPD will 
take high nicotine EC and refill liquids off the market, potentially affecting heavier 
smokers seeking higher nicotine delivery products.   
 
The fact that no licensed EC are yet on the market suggests that the licensing route to 
market is not commercially attractive. The absence of non-tobacco industry products 
going through the MHRA licensing process suggests that the process is inadvertently 
favouring larger manufacturers including the tobacco industry, which is likely to inhibit 
innovation in the prescription market.  
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Policy implications 
o From May 2016, following the introduction of the revised TPD, ECs will be more 
strictly regulated. As detailed elsewhere in the report, the information we present 
does not indicate widespread problems as a result of EC. Hence, the current 
regulatory structure appears broadly to have worked well although protecting non-
smoking children and ensuring the products on the market are as safe and effective 
as possible are clearly important goals. New regulations currently planned should 
be implemented to maximise the benefits of EC whilst minimising these risks. 
 
o An assessment of the impact of the TPD regulations on the UK EC market will be 
integral to its implementation. This should include the degree to which the 
availability of safe and effective products might be restricted.  
 
o Much of England’s strategy of tobacco harm reduction is predicated on the 
availability of medicinally licensed products that smokers want to use. Licensed ECs 
are yet to appear. A review of the MHRA EC licensing process therefore seems 
appropriate, including manufacturers’ costs, and potential impact. This could include 
a requirement for MHRA to adapt the processes and their costs to enable smaller 
manufacturers to apply, and to speed up the licensing process. The review could 
also assess potential demand for the EC prescription market and what types of 
products would be most appropriate to meet that demand.  
Prevalence in England / GB 
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4. Prevalence of e-cigarette use in 
England/Great Britain 
This chapter assesses the use of EC by adults and young people in England by drawing 
on recent surveys carried out in England and Great Britain (GB). A later chapter 
discusses EC prevalence internationally.  
 
Measures used 
One of the main issues in measuring EC use is the lack of consistent and appropriate 
terminology, for example some studies equate ever having used EC with current use of 
EC which is clearly inappropriate. We recommend that definitions of usage categories 
should be standardised similar to those used in smoking surveys. Appendix B lists the 
different measures used in surveys focused on in this report, and gives definitions used 
in the other studies included in this review.   
 
Use of e-cigarettes by adults 
First, we assess e-cigarette use in the adult population in England. We summarise 
various data sources to provide an overview of EC use among the general population, 
and then specifically smokers, recent and long-term ex-smokers, and never-smokers. 
The two main surveys used in this chapter are the Smoking Toolkit Study (STS) and the 
ASH Smokefree GB surveys. However, in addition to these surveys, findings from the 
Office for National Statistics Opinions and Lifestyle Survey (ONS survey), a randomised 
probability sample omnibus survey in GB, have also been included in this section 
although the exact question used is not available [13]; preliminary released data from 
Q1 2014 are reported here in advance of the complete data due for publication later in 
2015. 
 
Population use of e-cigarettes 
Of the available datasets, just two – the Smoking Toolkit Study (STS, England) and the 
ASH Smokefree GB adult surveys – provide information on population prevalence 
(Table 1). Using the STS, it is estimated that 5.5% of the adult population of England 
used EC in the first quarter of 2015 indicating a marked rise from 0.5% in 2011. The 
measure of use in the STS is compiled from four survey questions and assesses current 
use for any reason (Appendix B). A very similar estimate is obtained for GB using the 
2015 ASH survey, with 5.4% of the population estimated to be current (defined as tried 
EC and still use them, see Appendix B) EC users. This translates to about 2.6 million 
EC users in GB in 2015 [14](for comparison there are about nine million tobacco 
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smokers in GB and as discussed later, most EC users are smokers or ex-smokers). The 
ASH survey also assessed trial and about 17% of the adult GB population was 
estimated to have tried EC.  
 
Table 1: Adult EC current use1 
 
Source (date of data collection) Population 
Prevalence 
Never 
smokers 
Ex-smokers Smokers 
(‘Dual users’) 
ASH Smokefree GB adult 
survey  
(2015 - March) 
5.4% 0.2% 6.7% 17.6%  
Office for National Statistics  
(2014 - Q1) 
N/A 0.1% 4.8% 11.8% 
Smoking Toolkit Study  
(2015 – Q1) 
5.5% 0.2%2 3.3%2 21.2% 
 
1
For definitions of current use please see Appendix B. The ONS question is unavailable. 
2
Figures for never and long-term ex-smokers are derived from n=22489 never and long-term ex-smokers surveyed 
between November 2013 and March 2015
 
 
Never smokers and long-term ex-smokers 
All three surveys estimate current EC use among adult never smokers to be very rare at 
0.2% or less, and between 3% and 7% among ex-smokers – the latter estimates may 
vary because  in the STS recent ex-smokers (last-year) are not included in this category 
(Table 1). Prevalence of current EC use among recent ex-smokers in the STS was 
around 40% in the first quarter of 2015 [15].    
 
The ASH survey estimated that around 1.5% of never smokers and 16% of ex-smokers 
had ever tried EC.  
 
Smokers 
Recent surveys estimate that current EC use among smokers, sometimes referred to as 
‘dual users’ of cigarettes and e-cigarettes, is between 12 and 21% (Table 1). The 
prevalence of EC use among last-year smokers (defined as smokers and recent ex-
smokers) using the STS in England is estimated at 22.9% for any use of EC and 14.9% 
for daily EC use. The ASH 2015 survey indicated that 17.6% of current smokers use EC 
currently (18% of occasional and 17% of daily smokers); the same survey indicated that 
a small majority of smokers (59%) have now tried EC.  
 
The Q1 2014 ONS Survey data estimates for current use are considerably lower, 
suggesting that just under 12% of current smokers used EC in early 2014. The survey 
question/s used to determine this is/are not available to assess whether different ways 
of assessing use may be a reason for this discrepancy in findings.   
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The ASH survey indicates that about 60% of current EC users are current smokers, and 
about 40% are ex-smokers. The proportion of EC users among never smokers remains 
negligible.   
 
Summary 
Around one in 20 of the general adult population in England (and GB) use EC. Current 
EC users are almost exclusively smokers or ex-smokers. EC use among long-term ex-
smokers is considerably lower than among recent ex-smokers.  
 
Trends in e-cigarette use among adults 
Both the STS and ASH surveys demonstrate that there was a steady increase in EC 
use in the population from 2011 to 2013.  
 
Smoking Toolkit Study (STS) data 
The STS data indicate that this increase slowed down, even declining at the end of 
2014 from 5.3% in Q3 to 4.5% in Q4 (Figure 1). However, as Q1 data from 2015 show a 
recent upswing to 5.5%, this decline may have been temporary. The STS data show 
that alongside the increase in EC use, smoking of tobacco cigarettes declined. Overall 
nicotine use, ie any consumption via cigarette smoking, NRT use or EC use, has also 
declined.  
 
Figure 1: Prevalence of smoking and e-cigarette use among the adult English population 
(STS)  
 
From www.smokinginengland.info/latest-statistics/ 
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The overall pattern of EC use in the population is mirrored among last year smokers for 
whom EC prevalence increased from 2011, but declined from 22% for any use and 14% 
for daily use in Q3 2014, to 19% and 11% respectively in Q4 2014; however, any and 
daily use increased again to 23% and 15% respectively in Q1 2015 (Figure 2).  
 
 
Figure 2: Prevalence of e-cigarette use among last year smokers (STS) 
 
 
 
From www.smokinginengland.info/latest-statistics/  
 
ASH Smokefree GB adult survey 
The ASH surveys indicated a slowing down in the increase of EC use in the population 
between 2014 and 2015 and use among current smokers in 2015 remained at the 2014 
level (17.6% of smokers in 2014 and 2015). Use among ex-smokers increased from 
1.1% in 2012, to 4.5% in 2014 and 6.7% in 2015, whereas no increase in use was 
observed among never smokers over the last few years, remaining at 0.2% since 2013. 
This means that the increase in EC use observed overall was accounted for by an 
increase in use by ex-smokers. It is not clear to what extent this is due to smokers 
stopping smoking using EC or ex-smokers taking up ECs.  
 
Summary 
The prevalence of EC use among adults has plateaued. Most of the recent increase in 
use appears to be among ex-smokers. Cigarette smoking has declined over the period 
when EC use increased and overall nicotine use has also declined. These findings 
suggest that the advent of EC is not undermining and may be contributing to the long-
term decline in cigarette smoking.  
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Types and flavours of e-cigarettes used among adults 
When those who had tried EC in the 2015 ASH survey were asked about which EC they 
used first, 24% reported a disposable, 41% a rechargeable with replaceable pre-filled 
cartridges and 28% rechargeable with tank/reservoir filled with liquids (7% didn’t 
know/couldn’t remember). The different types were in the same order of popularity for 
first use regardless of smoking status (Figure 3).  
 
For those still using EC from the same survey, only 5% were now mostly using a 
disposable, 26% a rechargeable with replaceable pre-filled cartridges and 66% 
rechargeable with tank/reservoir filled with liquids (2% didn’t know/couldn’t remember). 
This suggests that a considerable proportion of those who continue to use EC 
over time switch to the tank models. Among EC users, ex-smokers were particularly 
likely to use tank models mostly and very few ex-smokers were using disposables 
(Figure 3). This is in agreement with findings reported in Chapter 6 of this report, where 
tank models were found to be associated with having quit smoking [16].  
 
 
Figure 3: Type of e-cigarettes first used and currently used (ASH Smokefree GB data 
2015) 
 
 
 
The ASH Smokefree GB 2015 adult survey also shows that the most popular flavour 
was tobacco flavour, followed by fruit and menthol flavours (Figure 4).  
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Figure 4: Use of different flavoured e-cigarettes (ASH Smokefree GB data 2015)  
 
 
 
Use of e-cigarettes among young people 
The main source for estimating smoking prevalence in England among youth is the 
’Smoking, drinking and drug use among young people’ surveys [17], however, EC use 
was first assessed in 2014 and these data are not yet available. This section therefore 
draws on the ASH Smokefree GB youth surveys to assess EC usage in young people, 
supplemented by a study in the North West of England, two cross-sectional national 
surveys in Wales and one national survey in Scotland. The measures used are detailed 
in Appendix B. 
 
In 2015, the ASH survey found that 12.7% of 11 to 18-year olds reported having tried 
EC; of these, 80.9% had only used one once or twice (10.2% of all respondents). 
Current EC use was considerably lower:  0.7% had used an EC sometimes but not 
more than once a month; 1.2% more than once a month but not weekly; and 0.5% 
weekly (Table 2). The prevalence of EC use (2.4% overall) among people aged 
between 11 and 18 was therefore lower than among the general population. In 
comparison, 21% of all 11 to 18-year olds reported having tried cigarettes, of whom 
54% only tried once (11.4% of all respondents). Current smoking was reported by a 
total of 6.7%; 2.7% smoked less than weekly and 4% at least weekly. 
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Experimentation increased with age: 2.9% of 11-year olds and 20.2% of 18-year olds 
had tried EC. In comparison, among 11-year olds, 3.9% had tried cigarettes (0.7% 
current smokers), whereas 40.9% of 18-year olds had tried cigarettes (14.3% current 
smokers).  
 
Use of EC was very closely linked with smoking status. Among never smokers, 0.3% 
used EC monthly or more often, compared with 10.0% of ever smokers and 19.1% of 
current smokers. The majority of EC users had tried tobacco cigarettes first (Table 2).  
 
Table 2: E-cigarette use among young people 
 Source Ever 
tried 
Use more 
than /at 
least once 
a month 
Use  more 
than once 
a week 
Use (at 
least 
monthly) 
in never 
smokers 
Those using 
e-cigarettes 
who had 
tried 
tobacco 
first 
ASH Smokefree GB youth 
survey (11-18 years) 1 
(2015 – March) 
12.7% 1.9% 0.5% 0.1% 63.7% 
Health Behaviour in School-
aged Children, Wales (11-16 
years)  
(Nov 2013 – Feb 2014) [18] 2 
12.3% 1.5% Not 
reported 
0.3% Not 
reported 
 
 
CHETS Wales survey 
(10—11 year olds)[19] 2014 
5.8% Not 
reported 
Not 
reported 
Not 
reported 
Not 
reported 
SALSUS Scotland survey 
(15 and 13 year olds)[20] 
2013/2014 
12%  
 
0.4% 
 
 
 
0% 0% Not 
reported 
 
1
For question on e-cigarette categories please see Appendix B.
 
Use more than/ at least once a month excludes 
those using more than once a week who are reported separately
 
2 
N=9055, use defined as at least monthly 
 
Similar findings have been observed in Scotland. A national survey carried out in 283 
schools across Scotland in late 2013/early 2014 involved more than 33,000 
schoolchildren aged 13 and 15 years old [20]. Seven per cent of 13-year olds, and 17% 
of 15-year olds, had ever used an EC. Trial was associated with smoking status – 4% of 
never smokers had tried EC (3% trying them once and 1% having tried a few times) 
compared with 24% of ever smokers, 39% of ex-smokers, 46% of occasional smokers 
and 66% of regular smokers. Eleven per cent of regular smokers and 6% of occasional 
smokers reported using e-cigarettes at least monthly. 
 
Very similar findings have been reported from a survey in Wales (Table 2). A survey of 
secondary schoolchildren was carried out under the auspices of the Health Behaviour of 
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School Children (HBSC) study and more than 9,000 participants aged 11–16 from 82 
schools were included [18]. Overall, 12.3% had tried EC, 1.5% were monthly users, 
compared with 12.1% reporting ever having smoked and 5.4% current smokers 
(reported smoking less than once a week or more frequently). Whilst many experimental 
EC users had never smoked, most regular EC users had also smoked tobacco. The 
authors commented that “the very low prevalence of regular use…suggests that e-
cigarettes are unlikely to be making a significant direct contribution to adolescent 
nicotine addiction”.  
 
Additionally, around 1,500 10 to 11-year olds were surveyed in Wales, from 75 schools 
in the CHETS Wales study [18, 19] (Table 2). Overall, 5.8% (n=87) had ever used an 
EC; most reported only using once (3.7%, n=55 overall) and only 2.1% (n=32) reported 
using them more than once. Again, EC use was associated with smoking. Just under 
half (47.6%) of those who reported having used tobacco had ever used an EC 
compared with 5.3% of never smokers. Controlling for other variables associated with 
EC use, parental use of EC and peer smoking remained significantly associated with 
having ever used an EC. Having ever used an EC was associated with weaker anti-
smoking intentions. Parental EC use was not associated with weakened anti-
smoking intentions whereas parental smoking was [19]. This study, published prior 
to the one above, concluded that EC represented a new form of experimentation with 
nicotine that was more common than tobacco usage. It also commented that the 
findings added “some tentative support for the hypothesis that use of e-cigarettes may 
increase children’s susceptibility to smoking”. However, as this was a cross-sectional 
survey, causal connections cannot be inferred. It is possible that children who had used 
EC would have smoked cigarettes in their absence and this could explain the 
relationship between intentions and EC usage (see below).  
 
An additional survey of schoolchildren has been carried out in England. Trading 
Standards in the North West of England have been running biennial surveys of 
schoolchildren since 2005. The 2013 findings on EC, smoking and alcohol were 
published [21]. The survey was not designed to be representative (no compliance or 
completion rates were collected) but instead “to provide a broad sample of students 
from a range of community types”. More than 100 schools participated and more than 
16,000 participants aged 14–17 years of age were included in the analyses. It is 
important to acknowledge that the question about EC was “Have you ever bought or 
tried electronic cigarettes?”, and this study cannot therefore add to knowledge on 
current usage. Around one in five of the sample had accessed EC, with access being 
higher in those who had experience of smoking. Around 5% of those who had never 
smoked cigarettes reported accessing EC; around half of ex-smokers and over two 
thirds of regular smokers had accessed them. Parental smoking and alcohol use were 
also associated with EC access.  
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Summary 
Regular use of EC among youth is rare with around 2% using at least monthly and 0.5% 
weekly. A minority of British youth report having tried EC (national estimates suggest 
around 12%). Whilst there was some experimentation with EC among never smokers, 
nearly all those using EC regularly were cigarette smokers.  
 
Trends in e-cigarette use among young people (ASH Smokefree GB youth) 
The ASH Smokefree GB youth surveys indicate that awareness of EC has increased 
markedly, with the proportion of individuals who had never heard of EC falling from 
33.1% in 2013 to 7.0% in 2015. Ever having tried EC also increased, from 4.5% in 
2013, to 8.1% in 2014, and to 12.7% in 2015. However, the proportion using an EC 
monthly or more frequently remained virtually unchanged from 2014 (1.6%) to 2015 
(1.7%). Over the same period, the proportion of regular smokers (at least weekly) 
remained at around 4% (2013: 4%, 2014: 3.6%, 2015: 4%).   
  
Type and flavour among youth 
The proportion of youth reporting current use was too small to assess the most 
frequently used types or flavours in current users, so Figures 5 and 6 include everyone 
who had tried an EC. One third had first used a tank model and the most popular 
flavours among triers by far were fruit flavours. The responses for adults and youth are 
not directly comparable given flavours were assessed for adult current EC users, but in 
the latter group, fruit flavours were less popular than tobacco flavours.  
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Figure 5: First type of e-cigarette tried by youth, ASH Smokefree GB youth survey, 2015 
 
 
 
Note: The proportion of youth reporting current use was too small to assess the most frequently used types. 
 
Figure 6: Last flavour tried by youth, ASH Smokefree GB youth survey, 2015 
 
 
 
Note: The proportion of youth reporting current use was too small to assess flavours in current users. 
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Concerns about impact of e-cigarette use on smoking 
Three main concerns raised about EC use are that they might 1) renormalise smoking 
2) reduce quitting and 3) act as a ‘gateway’ to smoking or nicotine uptake. An ultimate 
test for the first concern, and to some extent all three concerns, is the impact of EC use 
on smoking prevalence nationally which is explored first below. Evidence for 
effectiveness of EC on quitting smoking is explored in more detail in Chapter 6. Whilst 
other concerns have been raised such as renormalising the tobacco industry, we are 
only able to comment on issues pertaining to the objectives of our report. 
 
Recent trends in smoking prevalence   
Since EC arrived on the market in England, smoking prevalence has continued to 
decline among both adults and youth (Figures 1, 7 and 8). Evidence to date therefore 
conflicts with any suggestion that EC are renormalising smoking. Whilst other factors 
may be contributing to the decline in smoking, it is feasible that EC may be contributing 
to reductions in smoking over and above any underlying decline. 
 
 
Figure 7: Adult smoking prevalence in England 1980–20131  
 
 
 
 
 
 
                                            
 
1
 General Lifestyle Survey  aged 16+(1980-2010); Integrated Household Survey aged 18+ (2011). Diagram courtesy of ASH. 
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Figure 8: Prevalence of regular smoking among 11–15 year olds in England 1980–20142 
 
 
 
Please note: decimal places were not used in the published data.  
 
Gateway 
The gateway theory or hypothesis is commonly invoked in addiction discourse, broadly 
to suggest that the use of one drug (sometimes a legal one such as tobacco or alcohol) 
leads to the use of another drug (sometimes an illegal one) but its definition is 
contested. No clear provenance exists and its origin appears to derive from lay, 
academic and political models [22]. It is apparent that discussions about the natural 
progression of drug use observed in longitudinal studies of young people appear to 
have morphed into implicit conclusions on causality without any evidential backing. 
Some have argued that the effect could be causal if the use of one drug, biochemically 
or pharmacologically, sensitises the brains of users to the rewarding effects of other 
drugs [23] making the dependent use of these other drugs more likely. However, there 
are many plausible competing hypotheses for such a progression [24] including i) 
shared networks and opportunities to purchase the drugs; and ii) individual 
characteristics such as genetic predispositions or shared problematic environment.  
Academic experts have stated that the gateway concept “has been one of the most 
controversial hypotheses…in part because proponents and opponents of the hypothesis 
have not always been clear about what the hypothesis means and what policies it 
entails” [24]. Indeed, a recent analysis of gateway concluded “Although the concept of 
                                            
 
2
 Smoking drinking and drug use among young people in England surveys. Health and Social Care Information Centre, 2014.  
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the gateway theory is often treated as a straightforward scientific theory, its emergence 
is rather more complicated. In effect, it is a hybrid of popular, academic and media 
accounts – a construct retroactively assembled rather than one initially articulated as a 
coherent theory” [22]. 
 
Despite these serious and fatal flaws in the arguments, the use of the term ‘gateway’ is 
commonplace both in the academic literature and the lay press, particularly in relation to 
EC use and whether EC are a gateway to smoking. Some have suggested that if EC 
use increases at the same time as smoking increases then EC are acting as a gateway 
to smoking. Similarly, it’s been argued that if someone uses an EC first and then 
initiates smoking, EC are a gateway. These arguments are clearly erroneous. To give 
one example of the misuse of the gateway concept, a BMJ news item on the Moore et 
al., 2014 [18] cross-sectional study discussed above commented that “[EC} could be a 
gateway into smoking” [25]. 
 
Kandel recently argued that evidence from mice offers a biological basis for the 
sequence of nicotine to cocaine use in people [26], but there is limited evidence for this. 
In reality, the gateway theory is extremely difficult to test in humans. For example, a 
clean test of the gateway hypothesis in relation to EC and smoking would require 
randomising people to an environment with EC and one without, and then following 
them up over a number of years to assess uptake of EC and smoking.  
 
We strongly suggest that use of the gateway terminology be abandoned until it is 
clear how the theory can be tested in this field. Nevertheless, the use of EC and 
smoking requires careful surveillance in young people. The preferred option is that 
young people do not use EC but it would be preferable for a young person to use an EC 
instead of smoking, given the known relative risks of the EC and smoking cigarettes 
[10]. 
 
Summary 
Since EC were introduced to the market, smoking prevalence among adults and youth 
has declined. Hence there is no evidence to date that EC are renormalising smoking, 
instead it’s possible that their presence has contributed to further declines in smoking, 
or denormalisation of smoking. The gateway theory is ill defined and we suggest its use 
be abandoned until it is clear how it can be tested in this field. Whilst never smokers are 
experimenting with EC, the vast majority of youth who regularly use EC are smokers.  
Regular EC use in youth is rare. 
 
Summary of findings 
Adults: Around one in 20 adults in England (and Great Britain) use EC. Current EC 
users are almost exclusively smokers (~60%) or ex-smokers (~40%), that is smokers 
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who now use EC and have stopped smoking altogether. EC use among long-term ex-
smokers is considerably lower than among recent ex-smokers. Current EC use among 
never smokers is very low, estimated to be 0.2%. The prevalence of EC use plateaued 
between 2013-14, but appeared to be increasing again in 2015.  
 
Youth: Regular EC use among youth is rare with around 2% using at least monthly and 
0.5% weekly. EC use among young people remains lower than among adults: a minority 
of British youth report having tried EC (~13%). Whilst there was some experimentation 
with EC among never smoking youth, prevalence of use (at least monthly) among never 
smokers is 0.3% or less.  
 
Overall, the adult and youth data suggest that, despite some experimentation with EC 
among never smokers, EC are attracting few people who have never smoked into 
regular use.  
 
Trends in EC use and smoking: Since EC were introduced to the market, cigarette 
smoking among adults and youth has declined. In adults, overall nicotine use has also 
declined (not assessed for youth). These findings, to date, suggest that the advent of 
EC is not undermining, and may even be contributing to, the long-term decline in 
cigarette smoking.  
 
Policy implications 
o Trends in EC use among youth and adults should continue to be monitored using 
standardised definitions of use.  
 
o Given that around two-thirds of EC users also smoke, data are needed on the 
natural trajectory of ‘dual use’, ie whether dual use is more likely to lead to 
smoking cessation later or to sustain smoking (see also Chapter 6). 
 
o As per existing NICE guidance, all smokers should be supported to stop smoking 
completely, including ‘dual users’ who smoke and use EC.   
S 
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5. Smoking, e-cigarettes and inequalities 
Smoking and inequalities 
Whilst smoking prevalence overall has been declining over the past 50 years, smoking 
has become increasingly concentrated in more disadvantaged groups in society. Over 
the last decade, the gap between smoking in the different social groups has not 
narrowed (Figure 9) and some of the most disadvantaged groups in society (such as 
people with serious mental illness or prisoners) have shown no change in smoking 
prevalence over time (e.g. Figure 10). Furthermore, among smokers, the level of 
nicotine dependence increases systematically as deprivation increases [2]. A key 
challenge in tobacco control is therefore how to encourage smokers from 
disadvantaged groups to stop smoking.  
 
Whilst quitting cigarettes and all nicotine use should remain the main goal across all 
social groups, EC are of interest because, as with other cleaner nicotine delivery 
systems, they potentially offer a wide reach, low-cost, intervention to reduce smoking 
and improve health in these more deprived groups in society where smoking is elevated 
[2]. It is therefore important to examine the potential impact of EC on inequalities.  
 
Figure 9: Smoking trends by socioeconomic group status (GHS data)  
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Figure 10: Smoking trends and mental health [27] 
 
 
 
E-cigarette use and different social groups  
Earlier surveys in GB and internationally suggested a social gradient in the use of EC, 
with smokers of higher income and education being more likely to have used and tried 
[28, 29]. However, the 2015 ASH Smokefree GB adult 2015 survey indicated only small 
differences across groups, with lower socioeconomic groups slightly more likely to have 
tried and be using EC. At the population level, 14.4% of ABC1 groups (‘non-manual’ 
occupational groups) had tried EC compared with 19.4% in C2DE groups (‘manual’ 
occupational groups); 4.6% of ABC1 were still using EC compared with 6.3% of C2DE 
groups. Nevertheless, given the higher prevalence of smoking in C2DE groups, when 
examined within the smoker population by social class, 20.0% of ABC1 smokers 
compared with 16.0% of C2DE smokers were EC current users.  
 
The STS data surveys show an increase in EC use in all social groups between 2012 
and 2014 (Figures 11 and 12) but at a relatively similar rate such that socioeconomic 
differences are still apparent both for current and daily use of EC. 
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Figure 11: Current use of e-cigarettes by social class among last year smokers (STS 
data) 
 
 
From www.smokinginengland.info/latest-statistics/ 
 
Figure 12: Daily use of e-cigarettes by social class among last year smokers (STS data)  
 
 
From www.smokinginengland.info/latest-statistics/ 
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Nevertheless, EC are penetrating the lower socioeconomic groups. Figure 13 shows the 
social class breakdown of EC users by quarter over time, also derived from STS data.  
 
Figure 13: E-cigarette use by social class over time (STS data) 
 
 
From www.smokinginengland.info/latest-statistics/ 
E-cigarette use in other disadvantaged groups 
There are no GB data, to our knowledge, on EC use among groups where smoking 
prevalence is known to be very high, such as offenders and people with serious mental 
illness. There is emerging evidence on the effectiveness of EC in people with mental 
illness (see Chapter 6). However, to some extent, usage among these groups will be 
dependent on EC policies being introduced in prisons and mental health settings.  
 
Recent NICE guidance on smoking cessation in secondary care settings [30] 
recommended the implementation of smokefree policies in these settings, alongside 
advice to stop smoking and nicotine dependence treatment. Trusts are now 
implementing this guidance but many prohibit EC usage as well as cigarettes. The 
rationale for such prohibition is unclear. 
 
The South London and Maudsley NHS Foundation Trust (SLaM) was the second NHS 
mental health trust to go comprehensively smoke free in England. It has developed an 
EC policy alongside the smokefree policy which allows EC to be used in private spaces 
or grounds, although EC are not to be offered as first line treatment or replace tobacco 
cigarette smoking and can only be used as part of a care treatment pathway [31]. 
Currently, the use of disposable products or rechargeable models with cartridges is 
allowed (the latter only under supervision), but tanks are prohibited because of fears 
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that they might be used for new psychoactive substances (sometimes also known as 
‘legal highs’). The basis for this fear is being assessed and the use of tank models may 
be assessed in a restricted pilot shortly. During the first six months of the policy, the EC 
policy has been implemented smoothly.  
 
A more general concern has been raised that EC can be used as a vehicle for other 
drugs. This concern needs exploring and is not something that should be promoted. 
Nevertheless, if true, EC are likely to offer a less harmful delivery route for the drugs 
than smoking which could be the subject of research.  
 
Prisons are likely to introduce comprehensive smokefree policies over the next few 
years [32]. Similar to mental health trusts, it would seem inappropriate to prohibit EC 
and disposable EC are currently being piloted in at least three prisons [33]. 
Consideration should also be given to the use of other models of EC in pilots. The use 
of EC in prisons has been considered in other jurisdictions which should also be 
informative [34].  
 
Summary of findings 
Smoking is increasingly concentrated in disadvantaged groups who tend to be more 
dependent. EC potentially offer a wide reach, low-cost, intervention to reduce smoking 
and improve health in disadvantaged groups.  
 
Some health trusts and prisons have banned the use of EC which may 
disproportionately affect more disadvantaged smokers.  
 
Policy implications 
o Consideration could be given to a proactive strategy to encourage disadvantaged 
smokers to quit smoking as quickly as possible including the use of EC, where 
appropriate, to help reduce health inequalities caused by smoking. 
 
o EC should not routinely be treated in the same way as smoking. It is not 
appropriate to prohibit EC use in health trusts and prisons as part of smokefree 
policies unless there is a strong rationale to do so. 
E-cigarettes and smoking behaviour 
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6. E-cigarettes and smoking behaviour 
Introduction 
Studies examining the relationship between EC use and smoking behaviour have 
focused on two main questions to date: (1) do EC help people to quit when used on a 
quit attempt, and, (2) what is the effect of using EC while smoking, on reductions in 
smoke intake, cigarettes per day, quit attempts, and stopping smoking? Because EC 
use is a relatively new phenomenon and the products are constantly changing with 
technological innovation, the studies examining these questions to date are 
heterogeneous. As mentioned earlier, studies vary in their definitions of EC use, 
including ever use, which could include one puff, to studies that discriminate between 
daily and non-daily use. Additionally, it is evident that many of the studies were not 
originally designed to study the effects of EC use on smoking behaviour due to the 
absence of rigour and omitted/unmeasured variables. 
  
Current recommendations for use of e-cigarettes to quit 
The National Centre for Smoking Cessation and Training (NCSCT) has published 
current recommendations for practice regarding the use of EC for stopping smoking 
[35]. The NCSCT recommends that practitioners be open to EC use among smokers 
trying to quit, particularly if they have tried other methods of quitting and failed. The 
NCSCT also provides more detailed guidelines for smokers wanting to use EC to quit, 
including differences in puffing on EC versus regular cigarettes, the need to try different 
types of EC to find one that works for them, and that multi-sessional behavioural 
support is likely to improve their success of quitting. Some services have welcomed 
smokers who wish to stop with the help of EC [36].  
 
The NICE guidelines for tobacco harm reduction cover recommendations for the use of 
licensed EC for quitting, cutting down (reduction in cigarettes per day), and temporary 
abstinence [1], similar to NRT. Use for both cutting down and temporary abstinence 
have been shown to be precursors to quitting among smokers using NRT. As discussed 
in Chapter 3, no licensed EC are currently available. 
 
Use of e-cigarettes for stopping smoking   
STS data have shown that EC have quickly become the most common aid that smokers 
in England use to help them stop smoking (Figure 14). The rise in the use of EC as a 
stop smoking aid is occurring despite the fact that no licensed EC are available. 
Although the most effective way for stopping smoking, currently supported by the 
research literature [37, 38] is a combination of behavioural support (NHS in Figure 14) 
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and medication (NRT on prescription or Champix), the problem is that few smokers 
access these services, limiting their impact on population health.  
 
This section reviews the evidence regarding the use of EC for stopping smoking that 
has been published since the Cochrane Review [39] on the use of EC for smoking 
cessation and reduction (cutting down). The Cochrane Review is briefly summarised 
below.   
 
Figure 14: Support used in quit attempts
 
 
From: smokinginengland.info/latest-statistics 
 
Randomised controlled trials 
To date, two randomised controlled trials (RCTs) have tested the efficacy of EC for 
stopping smoking, one among smokers wanting to stop and the other among smokers 
not intending to quit within the next month [40, 41]. Both were among highly dependent 
smokers. A recent Cochrane Review of these RCTs [39] concluded that they 
demonstrated that EC with nicotine help smokers reduce their cigarette consumption 
and stop smoking compared with no nicotine EC (placebo). However, the authors 
cautioned that there was uncertainty in the findings, and gave their findings a ‘low’ 
confidence rating using GRADE standards. The Cochrane Review also considered 
observational studies of EC use and cessation. They concluded that these 
observational studies were generally consistent with the findings of RCTs. Since the 
Cochrane Review, one RCT[41], and a secondary analysis of one of the RCTs in the 
Cochrane Review[42] have been published and are discussed below. 
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O’Brien et al., 2015 [42] conducted a secondary analysis of the RCT data from Bullen et 
al., 2013 [43] to examine the effectiveness of EC with and without nicotine compared to 
the nicotine patch among individuals with mental illness (MI). They identified 86 
participants among the original 657 participants (all motivated to quit) using secondary 
data from the trial on reported use of any medications associated with MI. Overall, when 
compared to participants without MI, there were no significant differences for those with 
MI on the primary outcomes of smoking reduction and smoking cessation. One 
exception was that the six-month quit rate was higher among participants with MI in the 
patch condition compared to those without MI. Although not a primary outcome, there 
was evidence of a greater rate of relapse among participants with MI. In the analysis 
that only included participants with MI, there were no significant differences in quit rates 
across the three conditions, however participants allocated to 16mg EC showed greater 
smoking reduction than those allocated to patch. The authors concluded that EC 
appear to be equally effective for smoking cessation among individuals with and 
without MI, building on other promising research involving EC and people with MI.  
 
Adriaens et al., 2014 [41] conducted an eight-week RCT in Belgium with control where 
they randomised 48 smokers who did not want to quit to one of two conditions: (1) 
use of tank model EC, and training on how to use, with no encouragement to quit, and 
(2) no use of EC. Both groups attended similar periodic lab sessions over an eight-week 
period where measurements of craving, withdrawal, saliva cotinine, and expired-air CO 
levels were taken. Adriaens found that after eight weeks of use 34% of those given EC 
had quit smoking compared to 0% of those not given EC, the EC group also showed 
substantially greater cigarette reduction. After eight weeks, the group which did not 
receive EC at baseline was given EC, but no training on how to use the products. At the 
final eight-month follow-up, 19% of the original EC group and 25% of the control group 
(given EC at week eight) had quit smoking. Significant reductions in cigarette 
consumption were also found. 
 
Population studies  
One problem with RCTs is that because of the time taken to set up and implement trials, 
the EC used in the trials are often no longer available for sale by the time the research 
is published. This is problematic because many new EC enter onto the market and it is 
possible they may be more effective at delivering nicotine than the products used in the 
trial, and possibly more effective for smoking cessation. Additionally, the controlled 
environment of RCTs is unable to provide evidence of the effectiveness of EC in the 
real world where use is much more subject to external forces, such as availability, price 
and social norms around use. RCTs also reveal little about the attractiveness of the 
products and thus likely uptake of the products used and what happens after a 
successful or failed attempt to stop smoking with an EC in the long-term. 
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Observational and natural history studies are therefore important. Only one population-
based survey has examined the effectiveness of EC used during quit attempts. A large 
cross-sectional study of 5,863 English smokers who attempted to quit in the past year 
without using professional support  [29] found that those who used EC on their last quit 
attempt were more likely to quit than those who used over the counter NRT – (the most 
common help sought by smokers after EC, see Figure 14), or no quit aid, controlling for 
factors related to quitting. This study was, however, unable to explore prospective 
predictors of quitting, including pre-quit nicotine dependence. Still, this study offers 
some of the best evidence to date on the effectiveness of EC for use in quit attempts.  
 
Other recent population studies [16, 44, 45] have also examined the association 
between EC use and quitting. However, because these studies (1) included smokers 
who were already using EC at baseline, and (2) did not examine the use of EC during a 
specific quit attempt, we discuss them below in the section on use of EC while smoking.  
 
Pilot studies 
Polosa et al., 2014 [46] conducted a six-month pilot study of tank-type EC users with no 
control group among 72 smokers who did not want to quit (smokers were enrolled 
after rejecting participation in smoking cessation program at a hospital). At six 
months, they found significant 50% and 80% reductions in cigarette consumption, and a 
quit rate of 36% [46]. Another study by Polosa et al., 2014 [47] followed 71 vape shop 
customers (seven different shops) after their first visit to the shop. The first visit included 
instructions on how to use EC and encouragement to use their EC of choice to reduce 
their smoking, along with a telephone number they could call for help. At six and twelve 
months after their initial visit they found that the smokers reported significant 50% and 
80% reductions in cigarettes per day at six and twelve months, and that at six and 
twelve months, 42.2% and 40.8% had quit smoking. 
 
E-cigarettes and stop smoking services 
Some English stop smoking services and practitioners support the use of EC in quit 
attempts [48], and provide behavioural support for EC users trying to quit smoking. The 
most recent monitoring data from the stop smoking services show the self-reported 
success rates for different medications and nicotine-containing products used (Figure 
15). Data are not given by validated success rates but overall, 69% of those who self-
report stopping smoking are carbon-monoxide validated [49]. Hence, there are 
limitations with these data as they are self-reported success rates and it is possible that 
they may vary by treatment used. Additionally, the data are not adjusted for other 
factors, such as dependence, known to influence success rates, and it is likely that they 
emanate from a limited number of services who record unlicensed nicotine-containing 
products and who might therefore be more supportive of their use. Nevertheless, the 
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evidence is consistent with evidence from trials and other observational data that e-
cigarettes are likely to support successful quitting. 
 
Figure 15: Support used and stop smoking service self-reported quit rates3 
 
 
 
Note: Figures in brackets represent the number of quit attempts in which each type of support was used. The number of clients 
with recorded e-cigarette use is very small in comparison to those recorded to have used other types of support.  
 
 
Use of e-cigarettes while smoking  
Population studies 
Two studies using data drawn from a longitudinal population sample of more than 1,500 
smokers in GB recently examined the impact of EC use on quitting, considering the 
effects of frequency of EC used and type of EC. Brose et al., 2015 [45] found that 
respondents who used EC daily at baseline were more likely to make a quit attempt one 
year later, but were no more or less likely to quit than those who did not use EC. Daily 
EC use at follow-up was found to be associated with reduced cigarette consumption 
since baseline. No effects of non-daily EC use on quit attempts, quitting, or reduction in 
consumption were found. Using data from the same Internet Cohort GB study, 
Hitchman et al., 2015 [16] found differences in quitting between baseline and follow-up 
                                            
 
3
 Taken from Health and Social Care Information Centre. Statistics on NHS Stop Smoking Services in England - April 2014 to 
December 2014.Publication date: April 23, 2015 Source: Ref 47. http://www.hscic.gov.uk/catalogue/PUB17302 
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depending on the type and frequency of EC used at follow-up: compared to no EC use, 
non-daily cigalike users were less likely to have quit smoking since baseline, daily 
cigalike or non-daily tank users were no more or less likely to have quit, and daily tank 
users were more likely to have quit. Overall, the two studies showed that daily use of 
EC does not lead to lower cessation, and is associated with making quit attempts, 
cigarette reduction, and if tank-type EC is used, is associated with smoking cessation. 
Non-daily use of EC is not associated with quit-related outcomes, and may, if cigalike-
type EC are used, be associated with lower cessation.  
 
Supporting these findings, using data from a longitudinal  population study of smokers in 
two metropolitan areas in the US, Biener et al., 2015 [44] measured use and intensity of 
EC use at follow-up in a longitudinal sample of smokers at baseline from two US cities. 
Biener also found that it was only intensive EC users (used daily for at least one month) 
that were more likely to quit, less intensive EC users were no more likely to quit than 
those not using EC.  
 
There are limitations with these studies. For example, an unavoidable methodological 
problem is that only people who currently smoke are included in these studies meaning 
that smokers who switched completely to EC and stopped smoking are excluded. The 
efficacy of EC is thus invariably underestimated.  
 
A longitudinal telephone survey reported by Al-Delaimy et al., 2015 [50] among a 
sample of 368 current smokers from California at baseline (2011) investigated the 
relation between ‘ever have used’ versus ‘never will use’ EC, and making a quit attempt, 
a 20% reduction in cigarettes per month, and quitting for more than one month at follow-
up (2012). Al-Delaimy included smokers at baseline who at both baseline and follow-up 
reported the same EC status: never will use EC at both baseline and follow-up OR ever 
have used EC at both baseline and follow-up, excluding anyone who gave different 
responses. Also excluded were respondents who said they might use EC in the future at 
baseline or follow-up, and respondents who had never heard of EC, reducing sample 
size from n=980 to n=368. Al-Delaimy concluded that compared to smokers who 
reported they never will use EC, respondents who had ever used EC were significantly 
less likely to have reduced their cigarette consumption and quit at follow-up, with no 
differences reported of quit attempts at follow-up. This study has serious methodological 
problems that make its conclusions uninterpretable, first, the measure of EC use is ‘ever 
use’, which could include even a puff on an EC and second, they applied several 
exclusion criteria that are not clearly justified.  
 
Studies of smokers enrolled in smoking cessation programs 
Two recent studies have examined the use of EC among smokers enrolled in smoking 
cessation programmes in longitudinal studies [51, 52]. Pearson et al., 2015 [51] 
examined the relation between reporting using an EC for quitting at follow-up and 
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smoking cessation (30-day abstinence) in a sample of smokers enrolled in a web-based 
cessation programme in the US with three-month follow-up. Pearson illustrated how the 
relation between using EC to quit and successful smoking cessation depended on the 
factors that were adjusted for and how the data were analysed, finding that under some 
conditions EC use was related to being less likely to quit and in others there was no 
relationship. The authors concluded that caution needs to be exerted when interpreting 
observational studies of the effects of EC use on smoking cessation. 
 
Borderud et al., 2014 [52] examined whether any use of EC in the past 30 days was 
related to smoking cessation outcomes in a group of cancer patients enrolled in a 
smoking cessation programme in the US. When treating all smokers who dropped out of 
the study as smoking cessation failures, the authors found that any use of EC in the last 
30 days was related to being less likely to quit; however, this treatment of the data may 
have been problematic because more EC users than non-users dropped out of the 
study. No relationship between EC use in the last 30 days and smoking cessation was 
observed when drop-outs were excluded from the analyses. One potential problem with 
this study is the measure of any EC use in the last 30 days, as this could range from 
using an EC once in the last 30 days to using an EC daily for the past 30 days. As 
illustrated [16, 44, 45] and discussed in previous studies [51], measurements of EC use 
that do not fully capture frequency of use may influence the relation between EC use 
and smoking cessation. As with studies in the previous section, the Borderud study 
started with smokers who had tried EC but did not stop smoking. This, of course, 
seriously reduces the chance of detecting a positive effect.    
 
Summary of findings 
Recent studies support the Cochrane Review findings that EC can help people to quit 
smoking and reduce their cigarette consumption. There is also evidence that EC can 
encourage quitting or cigarette consumption reduction even among those not intending 
to quit or rejecting other support. It is not known whether current EC products are more 
or less effective than licensed stop-smoking medications, but they are much more 
popular, thereby providing an opportunity to expand the number of smokers stopping 
successfully. Some English stop smoking services and practitioners support the use of 
EC in quit attempts and provide behavioural support for EC users trying to quit smoking; 
self-reported quit rates are at least comparable to other treatments. The evidence on 
EC used alongside smoking on subsequent quitting of smoking is mixed.  
 
Policy implications 
o Smokers who have tried other methods of quitting without success could be 
encouraged to try EC to stop smoking and stop smoking services should support 
smokers using EC to quit by offering them behavioural support.  
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o Research should be commissioned in this area including: 
 longitudinal research on the use of EC, including smokers who have not used 
EC at the beginning of the study 
 the effects of using EC while smoking (temporary abstinence, cutting down) on 
quitting, and the effects of EC use among ex-smokers on relapse 
 research to clarify the factors that i) help smokers using EC to quit smoking and 
ii) deter smokers using EC from  quitting smoking, including different EC 
products/types and frequency of use and the addition of behavioural support, 
and how EC compare with other methods of quitting which have a strong 
evidence base 
  
o It would be helpful if emerging evidence on EC (including different types of EC) 
and how to use EC safely and effectively could be communicated to users and 
health professionals to maximise chances of successfully quitting smoking.   
7. Reasons for use and discontinuation 
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7. Reasons for use and discontinuation 
Reasons for using e-cigarettes 
Reasons for using EC have been assessed for adult smokers and ex-smokers in a 
number of different ways. Across different populations, help to quit smoking and harm 
reduction were the top reasons endorsed for using EC [44, 53-57].  
 
In the Internet Cohort GB survey, the list of possible reasons for using EC was extended 
after the first year (the survey was carried out in 2012, 2013 and 2014). Nevertheless, 
the most frequently endorsed reasons were health, to cut down and to quit smoking. 
These were endorsed by approximately 80% of current users at all three time points. 
The biggest change over time was recorded for ‘they are cheaper’ which appeared to be 
more popular in 2014 than 2013 (Table 3). Because of the way the question is phrased, 
a user endorsing a reason does not indicate that current use is for this particular reason, 
for example, 80% of current users agree that e-cigarettes may help you quit, but this 
does not mean that 80% of all users were using them in a quit attempt.  
 
Table 3: Internet cohort GB survey, reasons for using e-cigarettes (in order of frequency 
of endorsement in 2014) 
 
Which of the following were reasons for your using 
electronic cigarettes? (multiple responses possible) 
2012 (n=1031) 2013 (n=717) 2014 (n=505) 
They may make it easier for you to cut down 
the number of cigarettes you smoke 
81.0 78.1 79.4 
They may not be as bad for your health 81.7 79.8 79.2 
They might help you quit 81.8 79.9 79.0 
No tobacco smoke not asked 70.9 71.3 
They are cheaper not asked 36.1 65.5 
The smell or cleanliness not asked 65.4 65 
So you can use  them in places where 
smoking regular cigarettes is banned 
67.2 66.5 61 
They may be more socially acceptable not asked 55.8 54.3 
Because I enjoy it not asked 38.6 48.7 
They taste better 28.5 26.1 34.1 
Friends or family use them not asked 37.0 33.3 
The technology not asked 34.2 30.3 
A health professional advised you to do so not asked 16.7 16.4 
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The ASH Smokefree GB survey similarly found that EC users who were ex-smokers 
most frequently endorsed that they used or had used EC to help them stop smoking 
entirely (Table 4). Among smokers, this was the second most frequently endorsed 
reason, with curiosity being the most frequent reason. Smokers also often reported use 
to help them cut down on smoked tobacco, which was rarely reported by ex-smokers.    
 
Table 4: Reasons for use, ASH Smokefree GB adult survey, 2015 (weighted) 
 
 
I use/used electronic cigarettes… 
Smokers Ex-
smokers 
Just to give it a try 35% 29% 
To help me stop smoking tobacco entirely 30% 44% 
To help me reduce the amount of tobacco I smoke, but not stop 
completely 
29% 9% 
Because I had made an attempt to quit smoking already and I wanted 
an aid to help me keep off tobacco 
27% 35% 
To save money compared with smoking tobacco 24% 22% 
Because I felt I was addicted to smoking tobacco and could not stop 
using it even though I wanted to 
16% 17% 
Because I want to continue to smoke tobacco and I needed something 
to help deal with situations where I cannot smoke (e.g. workplaces, 
bars or restaurants) 
15% 8% 
To avoid putting those around me at risk due to second-hand tobacco 
smoke 
12% 13% 
Other 1% 3% 
 
A smaller number of surveys specifically assessed reasons for trial and gave the option 
of selecting curiosity, which was frequently endorsed as an important reason for 
experimentation in US adults from the general population as well as in a sample of 
opioid-dependent smokers [58-60].   
 
In youth, reasons for use has rarely been surveyed; one survey on reasons for 
experimentation among 1,175 students (middle school, high school and college) who 
had ever tried EC reported that the top three reasons for e-cigarette experimentation 
were curiosity (54.4%), the availability of appealing flavours (43.8%) and friends’ 
influence (31.6%). Compared with never smokers, however, ever cigarette smokers 
(OR=37.5, 95% CI: 5.0 to 283.3) and current cigarette smokers (OR=102.2, 95% CI: 
13.8 to 755.9) were many times more likely to say they tried EC to stop smoking [61].  
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A national survey in New Zealand of 3,127 year 10 students (mostly aged 14 to 15) also 
showed that the most frequently given reason for first trying EC was curiosity, 
irrespective of smoking status (64.5% overall) [62].    
 
Reasons not to use EC are rarely assessed. The ASH Smokers’ survey 2014 asked 
current and ex-smokers about advantages and disadvantages of EC. Among those who 
had never used EC, the three most important disadvantages were “They might be too 
expensive” (46%), “They might not be safe enough as a product” (39%) and “They 
might not satisfy my desire to smoke enough” (31%). 
 
Reasons why trial does not become use 
The rates of ever having tried an EC in the ASH GB Smokefree adult survey are more 
than three times those of current use; in the ASH GB Smokefree youth survey, about 
five times as many respondents had tried an EC as were currently using an EC, 
indicating that most of those who try EC do not progress to current use. A small 
number of surveys assessed why respondents who had tried an EC did not continue 
use.  
 
In a national sample of 3,878 US adults who reported ever trying EC, two-thirds did not 
continue to use them and this was linked to the main reason for trying them. Trial turned 
into continued use for only a minority (19%) of those who did not know their main 
reason for trying them or whose main reasons were curiosity, friends or family members 
or advertising. Continued use was more common for those whose main reasons for trial 
included help to quit smoking or reduce harm. Those who did not continue use were 
asked for their reasons for stopping. The reason most often given was that they were 
just experimenting (49%) [58].  
 
In the survey by Kong et al., reported previously, it appears that 98.5% of experimenting 
students did not continue use. Reasons for discontinuation were assessed but 
unfortunately the most commonly chosen response was ‘other’ (23.6%, open-ended 
responses included “I don’t like it”, “I just tried once”) followed by “uncool” (16.3%) and 
health risks (12.1%) [61].  
 
Some surveys can be used to assess why smokers may not continue to use EC. The 
ASH Smokers’ survey in 2014 indicates that disappointment with the help EC provide in 
reducing smoking urges may be an important reason. Among smokers who had tried 
EC but did not continue using them, 44% said that a disadvantage of the products was 
that “They might not satisfy my desire to smoke enough”. No other reason got a higher 
rate of agreement in this group. A high proportion of smokers who were currently using 
EC also stated this reason (37%), but the proportion was significantly (p<0.05) lower in 
ex-smokers who had used (32%) or were currently using EC (7%), suggesting that 
satisfaction with the device/s may be a correlate of stopping smoking.   
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Of concern is that data suggest that some smokers may not continue to use EC instead 
of smoking because of a misguided belief that EC would be harmful to their health. In 
the ASH Smokers’ survey 2014, the second most frequently endorsed disadvantage 
was “They might not be safe enough as a product” (35%) among smokers who had tried 
an EC but were not using one anymore. Similarly, in a survey of US respondents, 
among 227 respondents who had tried EC in the past, were no longer using them but 
were still smoking cigarettes [44], the most frequently endorsed reason was that EC 
didn’t feel enough like smoking cigarettes, followed by dislike of the taste and that they 
were bad for health. It would appear therefore that these respondents stopped EC use 
in favour of continuing to smoke more deadly cigarettes. 
 
Summary of findings 
A number of surveys in different populations provide evidence that reducing the harm 
from smoking (such as through cutting down on their cigarette consumption or helping 
with withdrawal during temporary abstinence) and the desire to quit smoking cigarettes 
are the most important reasons for using EC. Curiosity appears to play a major role in 
experimentation. Most trial of EC does not lead to regular use and while there is less 
evidence on why trial does not become regular use, it appears that trial due to curiosity 
is less likely to lead to regular use than trial for reasons such as stopping smoking or 
reducing harm. Dissatisfaction with products and safety concerns may deter continued 
EC use.  
 
Policy implications 
o Smokers frequently state that they are using EC to give up smoking. They should 
therefore be provided with advice and support to encourage them to quit smoking 
completely. 
 
o Other reasons for use include reducing the harm from smoking and such efforts 
should be supported but with a long-term goal of stopping smoking completely.  
Harm perceptions 
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8. Harm perceptions 
Perceptions of the harmfulness of EC are frequently assessed in surveys, most 
commonly relative to conventional tobacco cigarettes. However, a recent 
Eurobarometer survey [63] asked smokers in absolute terms whether EC were harmful 
to the health of those using them. Overall in Europe, 40.6% perceived EC as not 
harmful (UK: 48.6%), 28.5% as harmful (UK: 14.6%) and 30.9% did not know if they 
were or were not harmful (UK: 36.8%). 
 
Harm perception relative to cigarettes  
In GB, the ASH surveys and the Internet Cohort survey have included questions on the 
perceived relative harm of EC. These surveys consistently show that compared with 
conventional tobacco products, EC were perceived as less harmful by a small majority 
of respondents, but with a sizeable minority inaccurately judging them to be more 
harmful, about as harmful or being unsure about their relative risks. For example, 
in the 2015 ASH Smokefree GB adult survey, 2% thought that EC were more harmful 
than cigarettes, 20% equally harmful, 52% less harmful, 2% completely harmless and 
23% did not know.  
 
Harm perception differed by smoking status (χ2=104.05, p<0.001) and by EC use status 
(χ2=453.4, p<0.001) (Figure 15). Overall, smokers were more likely to judge EC to be 
less harmful compared with cigarettes (63.7%, including ‘completely harmless’) than ex-
smokers (55.6%), whereas never-smokers were least likely to judge EC as less harmful 
(51.2%, all p<0.05). A higher proportion of current EC users (87.4%) thought that they 
were less harmful compared with cigarettes than those who had tried but were not using 
(68.8%) or never-users (50.4%), among whom the proportion was lowest (all differences 
p<0.05). Perceptions among youth were similar to adults. For example, in the 2015 ASH 
Smokefree GB youth survey, 2% thought that EC were more harmful than cigarettes, 
21% equally harmful, 67% less harmful and 10% did not know.   
 
In the STS, the proportion believing EC to be less harmful appears to be even lower. 
Only 44.1% of current smokers in England between November 2014 and March 2015 
believed that EC were less harmful than cigarettes [15]. 
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Figure 15: Perceptions of relative harmfulness of e-cigarettes in comparison with 
tobacco cigarettes by e-cigarette use and smoking status. ASH Smokefree GB adult 
surveys (weighted) 
 
 
 
Trends in harm perceptions relative to cigarettes over time 
Since 2013, perceptions of the relative harmfulness of EC have become less accurate. 
Significantly larger proportions perceived EC to be at least as harmful as cigarettes in 
2014 than in 2013 both in the Internet Cohort GB surveys (Figure 16) and in the ASH 
youth surveys (Figure 17 [64]). In the Internet Cohort GB survey, there was no 
significant change from 2012 to 2013, but from 2013 to 2014 the proportion thinking that 
EC were less harmful decreased in favour of equally or more harmful (p<0.001). For 
youth, between 2013 and 2014, the decrease in the proportion endorsing ‘less harmful’ 
and the increase in the proportion endorsing ‘equally harmful’ were significant (p<0.01). 
There were no significant changes in the proportion endorsing ‘more harmful’ or ‘don’t 
know’.  
 
In the ASH adult surveys, data on harm perception are available for 2013 to 2015 
(Figure 17). In line with the other GB surveys, this survey found a steep increase in the 
proportion perceiving EC to be equally harmful as cigarettes (p<0.001).  
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Figure 16: Perceptions of relative harmfulness of e-cigarettes in comparison with 
tobacco cigarettes. Internet Cohort GB surveys (N=1,209 respondents with data at all 
three time points) 
 
 
 
Figure 17: Perceptions of relative harmfulness of e-cigarettes in comparison with 
tobacco cigarettes. ASH Smokefree GB adult surveys (weighted) 
 
 
Notes: “Less harmful” includes those saying “Electronic cigarettes are completely harmless”. “Not applicable – I do 
not think regular cigarettes are harmful” not shown (2013: 1.2%, 2014: 0.9%, 2015: 0.8%) 
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Figure 18: Perceptions of relative harmfulness of e-cigarettes in comparison with 
tobacco cigarettes. ASH Smokefree GB youth surveys (2013 and 2014) taken from 
Eastwood et al., in press[64]. 
 
 
 
Surveys from the US also suggest that from 2010 to 2013, the proportion of current 
smokers aware of EC who believed that EC were less harmful than smoking cigarettes 
declined considerably [65]. Youth in the US appear to have a less realistic perception of 
the relative harm of EC compared with cigarettes than UK youth. In the 2012 National 
Youth Tobacco Survey, of those who were aware of EC, around one-third perceived 
them to be less harmful than cigarettes and around half were unsure [66, 67]. 
 
The ASH Smokefree GB youth survey in 2013 and 2014 further included a question on 
the harm of EC to persons around a user. Again, the proportion who thought them less 
harmful than traditional cigarettes decreased from 2013 to 2014 (p<0.05), and the 
proportion who thought they caused similar levels of harm increased (p<0.01) (Figure 
19).  
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Figure 19: Perceptions of relative harmfulness of e-cigarettes to people around the user. 
ASH Smokefree GB youth surveys  
 
 
 
Harm perception relative to nicotine replacement therapy (NRT) 
The ASH Smokers’ survey in 2014 asked respondents about their perception of EC 
compared with NRT (Table 20). The largest group of respondents thought EC were 
about as safe. Notably, a higher proportion thought that EC were safer than NRT than 
believed that NRT was safer than EC. This was particularly pronounced in current EC 
users. 
 
Table 5: Relative harm perception by e-cigarette use status ASH Smokers’ survey 2014 
 
 E-cigarette use status 
 Never Current Ex Total 
 39.10% 21.30% 39.70%  
 (n=470) (n=256) (n=477) (n=1203) 
Compared to NRT     
Safer 14 (66) 28.1 (72) 22 (105) 20.2 (243) 
About as safe 28.1 (132) 44.1 (113) 35.6 (170) 34.5 (415) 
Less safe 16.2 (76) 6.3 (16) 13 (62) 12.8 (154) 
Don't know 41.7 (196) 21.5 (55) 29.4 (140)  32.5 (391) 
 
One US survey of 1,400 current and former smokers also assessed expected outcomes 
of using EC compared with NRT [68]. EC were perceived to be less risky, cost less, 
cause fewer negative physical feelings, taste better, provide more satisfaction, and be 
better at reducing craving, negative affect, and stress.  
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Summary of findings 
Although the majority of adults and youth still correctly perceive EC to be less harmful 
than tobacco cigarettes, there has been an overall shift towards the inaccurate 
perception of EC being at least as harmful as cigarettes over the last year, for both 
groups. Intriguingly, there is also some evidence that people believe EC to be less 
harmful than medicinal nicotine replacement therapy (NRT).  
 
Policy implications  
o Clear and accurate information on relative harm of nicotine, EC and tobacco 
cigarettes is needed urgently (see also Chapter 10). 
 
o Research is needed to explore how health perceptions of EC are developed, in 
relation to tobacco cigarettes and NRT, and how they can be influenced.  
8. EC, nicotine content and delivery 
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9. E-cigarettes, nicotine content and 
delivery 
Background 
We have undertaken a review of available evidence concerning nicotine released by 
EC. The review is divided into four parts, covering nicotine that EC use (vaping) 
releases into ambient air, nicotine content of e-liquid, nicotine content in e-vapour, and 
nicotine delivery to EC users (vapers). The main concern with nicotine in EC relates to 
the question of whether EC use exposes users or bystanders to the risk of nicotine 
poisoning. For this reason, we start with a short introductory review of this topic. 
 
Toxicity of nicotine 
Nicotine in the form of tobacco and more recently NRT has been available to thousands 
of millions of people and large numbers of them, including small children, have ingested 
considerable doses of nicotine. Fatal nicotine poisoning, however, is extremely rare. 
This fact strongly contradicts the often-repeated claim that an ingestion of 30-60mg of 
nicotine is fatal. The source of this claim proved difficult to locate – textbooks just cite 
older textbooks. Eventually, the assertion was found to be based on dubious self-
experiments conducted in the 1890s [69].  
 
We are aware of one unconfirmed newspaper report of a fatal poisoning of a two-year 
old child [70] and of three published case studies of small children who drank e-liquid. A 
two-year old was admitted to hospital with vomiting, ataxia, and lethargy, and was 
discharged after 24 hours of observation [71]. In the second report, an 18-month old girl 
drank 24mg nicotine in e-liquid, vomited and was irritable, and recovered fully within an 
hour or so [72]. The third article presented a case of a 30-month old child suspected to 
have ingested e-liquid. The quantity of e-liquid was uncertain and the child was 
asymptomatic with all clinical observations reported to be normal [73].  
 
With the increase in EC use, there has been an increase in calls to poison centres 
following accidental exposures but these remain lower than calls following such 
exposure from tobacco and none resulted in any serious harm [74] (see next chapter for 
UK data). Serious nicotine poisoning seems normally prevented by the fact that 
relatively low doses of nicotine cause nausea and vomiting, which stops users from 
further intake.  
 
Apart from accidental poisoning, nicotine has also been used in suicide attempts. 
Suicide attempts with large amounts of pesticides containing nicotine sulphate often 
succeed [75] but completed suicides using e-liquids are extremely rare. Where adults 
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drank up to 1,500mg of nicotine in e-liquid, the result was vomiting and recovery within 
a few hours [76]. One fatal outcome was recorded with 3,950mg of nicotine found in 
gastric content. The victim seems to have drunk three vials of e-liquid totalling over 
10,000mg of nicotine[76]. An intravenous injection of unknown quantity of e-liquid also 
resulted in death [77].  
 
E-liquid normally comes in 10ml bottles containing up to 360mg of nicotine (see below). 
This poses no risk to vapers if used as intended. The liquid however should be in 
‘childproof’ packaging to prevent small children, who may find the flavouring appealing, 
from drinking it. This seems to have been widely accepted by the EC industry. All e-
liquids we have seen so far in the UK and globally were sold in child-resistant 
packaging.  
 
Review methods 
We searched the US National Library of Medicine (Pubmed) using the following search 
terms: ((cotinine OR nicotine) AND (blood OR plasma OR urine OR saliva OR liquid OR 
aerosol OR pharmacokinetic$)) AND (electronic cigarette$ OR e-cig$ OR ENDS). This 
search returned 161 records. The abstracts of all records were screened.  
 
Papers were included if they were peer-reviewed and presented data regarding nicotine 
in e-liquid, aerosol, or body fluids (blood, saliva or urine). Studies that reported data on 
blood, salivary, or urine cotinine were also included. 
 
A total of 112 records were excluded as they did not contain any relevant information, 
leaving 49 records. The full papers of these records were retrieved and reviewed. 
 
From the full text review, 25 studies provided data regarding nicotine content of ambient 
air, e-liquid and vapour, and 16 provided data on nicotine delivery to users. The 
remaining eight papers did not contain any relevant information. Three further relevant 
papers were published during the writing of this report and were also included. 
 
Nicotine in ambient air, e-liquid and e-vapour 
We identified five studies of nicotine in ambient air, 14 studies of nicotine in e-liquid and 
nine studies of nicotine vapour. The results are summarised below. We tabulate the 
results where appropriate and provide a narrative summary where there are only a few 
studies available. Each section is concluded with a brief summary.  
 
Passive vaping: Nicotine from e-cigarette use in ambient air 
Four studies examined nicotine exposure from passive vaping. Long et al., 2014 
measured nicotine content of EC exhalations. EC exhalations contained eight times less 
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nicotine than cigarette exhalations [78]. Estimating environmental nicotine exposure, 
however, has to take into account the fact that side-stream smoke (ie the smoke from 
the lighted end of the cigarette, which is produced regardless of whether the smoker is 
puffing or not) accounts for some 85% of passive smoking and there is no side-stream 
EC vapour. A study measuring nicotine residue on surfaces in houses of smokers and 
vapers reported only negligible levels from vaping, 169 times lower than from smoking 
[79].  
 
Colard et al., 2015 describe a model for estimating environmental workplace exposure 
[80]. The model predicts much lower nicotine exposure from vaping than from smoking, 
at levels negligible in health terms. 
 
Goniewicz and Lee 2014 found that nicotine from EC vapour gets deposited on 
surfaces, but at very low levels [81]. This poses no concerns regarding exposure to 
bystanders. At the highest concentration recorded (550 μg/m2), an infant would need to 
lick over 30 square metres of exposed surface to obtain 1mg of nicotine.   
 
Ballbe et al., 2014 provide the most informative data collected to date as this study 
measured the actual levels of airborne nicotine in homes of ex-smokers who live either 
with smokers (N=25) or with vapers (N=5) and also in 24 control homes [82]. The study 
also measured salivary and urinary cotinine in partners of smokers and vapers. As 
expected, there was little nicotine in non-smokers’ homes. The air in the homes of 
vapers contained six times less nicotine than the air in the homes of smokers. There 
was less of a difference between cotinine levels of partners of vapers and smokers (1.4 
to 2 fold difference), most likely due to some ‘ex-smokers’ still occasionally smoking, but 
even with this possible contamination, the nicotine levels absorbed via passive vaping 
were negligible. Partners of vapers had mean cotinine concentrations of 0.19 ng/ml in 
saliva and 1.75 ng/ml in urine, which is about 1,000 times less than the concentrations 
seen in smokers and similar to levels generated by eating a tomato [83].  
 
Summary 
EC release negligible levels of nicotine into ambient air with no identified health risks to 
bystanders. 
 
Nicotine in e-liquids 
Fourteen studies tested more than 400 different e-liquids, mainly to check the accuracy 
of product labelling. Their results are summarised in Table 6, updated from an earlier 
review by Cheng et al., 2014 [84].  
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Table 6: Nicotine in refill solutions, cartridges and aerosols of e-cigarette products  
(Adjusted from Cheng et al. 2014) 
Study Matrix Units Nicotine level Maximum deviation 
from label* 
Westenberger 
[85] 
 
Cartridge mg/cartridge 0.00 to 6.76 N.A. 
Aerosol μg/100mLpuff 0.35 to 43.2 N.A. 
Refill solution μg/mL N.D. to 25.6 N.A. 
 Cartridge mg/cartridge 0.00 to 6.76 N.A. 
Cobb et al 
[86] 
Cartridge mg/cartridge 3.23±0.5 to 
4.07±0.54 
–80 to –77%† 
 Aerosol μg/35 mL 
puff 
0.3 for puffs 11 to 
50 to 1 for puffs 1 to 
10 
N.A. 
Trehy et al 
[87] 
Refill solutions mg/mL 0 to 25.6 –100 to 100%† 
Cartridge mg/cartridge 0 to 21.8 –100 to 100%† 
Aerosol μg/100 mL 
puff 
0 to 43.2 N.A. 
Cheah et al 
[88] 
Cartridge mg/cartridge 0.00 to 15.3 –89 to 105%† 
Pellegrino et 
al [89] 
Cartridge % W/W <0.001 to 0.25 N.A. 
Aerosol mg/m3 <0.01 to 6.21 N.A. 
McAuley et al 
[90] 
Indoor air ng/L 538 to 8770 N.A. 
     
Goniewicz et 
al [91] 
Refill solution mg 0±0.0 to 25±1.1 –75 to 28% 
Cartridge mg 0±0.0 to 19±0.5 –89 to 25% 
Aerosol mg/150 puffs 0.3±0.2 to 
8.7±1.0 
N.A. 
Etter et al [92] Refill solution mg/mL N.D. to 29.0 –15 to 21%† 
Kirschner et 
al [93] 
Refill solution mg/mL 14.8±0.2 to 
87.2±2.7 
–50 to 40%† 
Cameron et al 
[94] 
Refill solution mg/mL 8.5±0.16 to 
22.2±0.62 
–66 to 42%† 
     
Goniewicz et 
al [95] 
Liquids mg/mL N.D. to 36.6 
(150.3 ‘pure 
nicotine’) 
-92 to 104% 
Geiss et al 
[96] 
Liquids mg/mL N.D. to 20.8 -0 to 16% 
Kavvalakis et 
al [97] 
Liquids %w/v 1.01 to 1.62 -17 to +6% 
Farsalinos et 
al [98] 
Liquids mg/ml Labelled 12-18 -21 to +22% 
*Deviation from label = (measured value – labelled value) * 100/labelled value.   
†Calculation performed by this analysis based on reported data in each study. 
N.A. = not available; N.D. = none detected. 
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A range of analytical methods was used, which may have contributed some variation. 
There is no established standard and different studies use different approaches. Cheah 
et al., used gas chromatography coupled with flame ionization detector [88]; Etter et al., 
gas chromatography coupled with mass spectrometry and ultra high-performance liquid 
chromatography coupled with diode array detector [92]; McAuley et al., gas 
chromatography coupled with nitrogen-phosphorus detector [90]; Goniewicz et al., gas 
chromatography coupled with thermionic specific detector [95]; Trehy et al., high-
performance liquid chromatography coupled with diode array detector [87]; 
Westenberger high-performance liquid chromatography coupled with ultraviolet/ visible 
spectroscopic detector [85]; Kubica et al., liquid chromatography coupled with tandem 
mass spectrometry [99]; and Kirschner et al., liquid chromatography coupled with time-
of-flight mass spectrometry [93]. 
 
The data generated so far provide answers to three questions: 
 
Do e-liquids pose a poisoning hazard?  
The vast majority of vapers use ‘ready-made’ liquids in 10ml bottles, but some 
aficionados, primarily in the US, buy high concentration nicotine solutions in larger 
quantities for DIY dilution. An e-liquid was identified labelled as containing 210mg/ml 
which in fact contained only 150mg/ml [95] but even this may pose risk if ingested in 
larger volume. DIY liquids are rarely used in Europe, but for spurious reasons, Europe is 
poised to prohibit sales of products with nicotine concentrations above 20mg/ml. When 
this happens, the popularity of DIY e-liquids among dependent vapers, who now cannot 
access the products they need but can mix them themselves at home at low cost, may 
increase.  
 
‘Ready-made’ e-liquids come in strengths of up to 36mg/ml nicotine, with the highest 
concentration recorded of 36.6mg/ml. This poses no risk of nicotine poisoning if used as 
intended. An overenthusiastic vaper, like someone who is over-smoking, receives a 
reliable warning via nausea. If the 10ml bottle of e-liquid was drunk, it would cause 
nausea and vomiting but would be unlikely to inflict serious harm. To protect young 
children from accidental exposure though, e-liquids should be in ‘childproof’ packaging. 
 
How accurate is product labelling?  
The real content exceeded markedly the labelled concentration only in samples where 
the declared content was very low (6mg/ml) and the real concentrations ranged up to 
12mg/ml (ie still low levels). The most striking examples of inaccurate labelling 
concerned much lower nicotine levels than those declared in e-liquids confiscated in 
Singapore where EC are banned, for example, a liquid labelled as containing 24mg of 
nicotine contained only 3mg [88]. This however was most likely due to samples being 
several years old. Market competition seems to have led to improved standards as 
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poorly labelled products are now less common and overall the labelling accuracy has 
improved.  For instance in the latest study which sampled 263 liquids from 13 
manufacturers, the correlation between the declared and measured concentrations was 
r=0.94 with the samples ranging from -17% to +6% of the declared value [85]. In 
another study testing the five most popular EC brands, the consistency of nicotine 
content across different batches of nicotine cartridges of the same products was found 
to be within the accuracy required from medicinal nebulisers [100]. Given the generally 
adequate labelling accuracy and the fact that the actual nicotine intake by vapers is 
dictated by a host of other factors discussed below, the accuracy of labelling of common 
e-liquids poses no major concerns.   
 
Is there is a risk from e-liquids inaccurately labelled as containing 0 nicotine?  
All samples labelled as containing 0 nicotine were nicotine free in the newer studies, but 
three early studies found nicotine in some samples of ‘0 nicotine’ e-liquids. One sample 
reported in 2011 was clearly mislabelled [87] but in all other cases, only trace 
contamination was detected (below 1mg/ml). This would have no central effect on 
users.  
 
Summary 
Poorly labelled e-liquid and e-cartridges mostly contained less nicotine than declared 
and so posed no risk to users. The accuracy of product labelling currently raises no 
major concerns.  
 
Nicotine in e-vapour 
A number of studies evaluated nicotine in EC vapour generated by puffing machines. A 
recent experiment [101] has shown that parameters of puffing topography, especially 
puff duration and puff frequency, have a major influence on nicotine delivery. This poses 
a serious problem in interpreting the existing studies. The key parameters used by 
puffing machines differ widely across studies, and may not correspond well or at all with 
vapers’ behaviour generally and especially with the way individual EC products are 
used. To illustrate the point, Table 7 below, from Cheng et al. 2014 [84], shows the wide 
range of settings used in different studies. (Table 7 includes some unpublished studies).  
 
Table 7. Settings of EC puffing parameters. From Cheng et al 2014 [84].  
 
Study Puff volume 
(mL) 
Puff interval 
(s) 
Puff duration 
(s) 
Puffs/session Smoking 
machine 
Goniewicz et al [100] 70 10 1.8 15 Palaczbot* 
Pellegrino et al [89] 498 8 3 16 Aspiration 
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Ingebrethsen [102] 55 30 2 to 4 10 Lab-built device 
McAuley et al [90] 50 30 4 50 SCSM 
Trehy et al [87] 100 60 2 30 Lab-built device 
Williams & Talbot 
[103] 
N.A. 60 2.2 10/11 Lab-built device 
Cobb et al[86] 35 60 2 ≥50 Machine ISO 
Trtchounian et al 
[104] 
N.A. 60 2.2 10 Lab-built Puff 
box 
Uchiyama et al [105] N.A. N.A. N.A. N.A. Premium 
Smoker 
Westenberger [85] 100 60 N.A. N.A. Lab-built device 
Laugesen [106] 38, 58 N.A. N.A. N.A. Syringe 
N.A., not available. 
 
For instance, the average puff duration in experienced vapers is 2.8 seconds [101], but 
some studies used puffs lasting for up to 4 seconds. This can overheat the e-liquid and 
provide unrealistically high readings (see Chapter 11).   
 
Although it would be feasible to establish some empirical standards, eg of puff duration 
and frequency, by observing vapers, any general standard would have to average 
values across different products. As different products, and especially products from 
different ‘generations’, are used differently, such a blanket regimen would still provide 
inaccurate and potentially misleading information.  
 
A recent study discovered another serious problem with trying to make sense of nicotine 
content in e-vapour. Across five common e-liquids with middle ranges of strength, the 
actual nicotine concentration in the e-liquid had almost no relationship with the nicotine 
content in vapour when the devices were puffed on by a machine at a standard rate 
[100]. The e-liquid of course had to contain a certain minimal level of nicotine as with 
little or no nicotine in e-liquid, there would be little or no nicotine in vapour. This finding 
concerning machine testing also does not mean that nicotine levels in e-liquids are 
irrelevant for EC users. Although EC technology is developing to maximise nicotine 
delivery, a vaper seeking high blood nicotine levels is likely to struggle to achieve them 
with a weak e-liquid. The reason for the low correlation between nicotine in e-liquid and 
in e-vapour is that the battery output, type of wicks, ventilation holes and other 
mechanical characteristics of each individual EC product determine how much vapour 
and nicotine is released – before the individual puffing style and preferences generate 
yet another key determinant of nicotine delivery to users. 
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These findings have an important implication. Above the necessary minimum level of 
nicotine, nicotine concentrations in e-liquid and even the concentrations in vapour, if 
measured by standard puffing schedules, are of limited relevance. For light smokers, 
18mg/ml ‘mild’ e-liquid may be sufficient, but they may also prefer a stronger liquid and 
take shorter and less frequent puffs. A heavy smoker who would be expected to prefer a 
28mg/ml ‘strong’ liquid may in fact chose a ‘moderate’ strength if they favour long and 
frequent puffs.  
 
In real-life use, vapers have no way of knowing in advance what liquid strength and 
product characteristics they will prefer. As with other consumer products of this type, 
such as cigarettes, coffee and soft drinks, vapers have to try several EC models and 
different e-liquids before settling on a preferred product that matches their preferences.  
 
For practical purposes, general labelling of the strength of e-liquid, along the lines used 
for indicating coffee strength, may provide sufficient information for consumers. The 
current vapers’ preferences suggest as a rough rule of thumb that ‘mild’ equates to 16–
20mg/ml, ‘medium’ to 21–26mg/ml and ‘strong’ to 27–36mg/ml.  
 
Translating these findings into regulatory recommendations, it would seem that 
regulation to enforce standard nicotine delivery may not be needed because nicotine 
delivery is influenced by a host of factors, including user puffing preferences, and 
because consumer preferences differ. EC products will hopefully continue to evolve 
guided by differential market success, with the result that more smokers find EC helpful 
and switch to them. 
  
Summary  
Across the middle range of nicotine levels, nicotine delivery to vapour is determined 
primarily by mechanical and electrical characteristics of EC products and by the 
duration and frequency of puffs. General labelling of the strength of e-liquids, along the 
lines used for indicating coffee strength (eg mild, medium and strong), is likely to 
provide sufficient information for consumers. 
 
Nicotine delivery to e-cigarette users 
To assess nicotine intake from EC, a number of studies took blood samples from 
smokers during and after vaping. Table 8 summarises data from 17 studies that 
investigated nicotine delivery from EC in humans. The narrative description of the 
studies and additional details concerning their findings are presented in Appendix C.  
 
The two key questions in this field are:  
a) How much nicotine EC deliver compared to cigarettes, and  
b) How fast EC deliver nicotine compared to cigarettes.  
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As in every new field, methodological problems limit the usefulness of some of the data 
collected so far. Two problems in particular are prominent. 
 
1) Almost all studies used prescribed puffing regimes, sometimes derived from 
observations of smokers rather than vapers. We described above the evidence that 
puffing schedules have a major influence on nicotine delivery to vapour. Puffing 
schedules that do not correspond with vapers’ behaviour are thus unlikely to provide 
realistic nicotine delivery data. Only three studies allowed vapers to puff ad-lib on first 
use.  
 
2) Regarding the question of the speed of nicotine delivery, all existing studies started 
blood sampling only after five minutes of vaping. Cigarettes provide peak nicotine 
plasma levels very quickly (eg peak arterial nicotine concentrations of around 20ng/ml 
nicotine are reached within 20 seconds of starting to puff on an cigarette [107]). Data 
collected so far do not allow an appraisal of whether EC are approaching cigarettes in 
this key parameter.   
Despite these limitations, the studies above have generated several strands of useful 
information on how much nicotine vapers obtain over time and how this compares with 
nicotine intake from cigarettes.  
 
Cotinine is a metabolite of nicotine with a long half-life which shows nicotine exposure 
over time. Cotinine data are thus not influenced by the laboratory puffing schedules. 
Some studies suggest that experienced vapers can, over time, reach nicotine levels 
comparable to those obtained from smoking [108-110], although others have found 
plasma or salivary cotinine levels that are still lower than those observed in daily 
smokers [111-113]. 
 
Cigalike EC deliver lower levels of nicotine than cigarettes [114-116], especially to 
novice users [117-119]. Vapers obtain slightly more nicotine from them with practice, 
but nicotine delivery is comparatively low and slow [115]. Experienced users can obtain 
a rise in blood nicotine concentration of between 8 and 16ng/ml [120, 121]. Tank 
systems deliver nicotine more efficiently than cigalikes and somewhat faster [120, 122, 
123].  
 
Overall, the data indicate that within five minutes of use of a cigalike EC, blood nicotine 
levels can rise by approximately 5ng/ml. For comparison, after chewing a piece of 2mg 
nicotine chewing gum, peak plasma concentrations of 3–5ng/ml are observed within 
approximately 30 minutes [124, 125]. For experienced users of tank systems the 
increase in blood nicotine concentration within five minutes of use can be 3–4 times 
higher.  
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Speed of nicotine delivery seems important for smokers’ satisfaction. Cigarettes deliver 
nicotine very fast via the lungs. It is likely that to out-compete cigarettes, EC will need to 
provide nicotine via the lungs as well. Although some EC products may already provide 
a degree of lung absorption, most nicotine is probably delivered via a much slower route 
through buccal mucosa and upper airways, in a way that is closer to the delivery from 
nicotine replacement medications than to the delivery from cigarettes. 
 
This tallies with two other observations. Vapers feel they are less dependent on EC than 
they were on cigarettes [126]; and non-smokers experimenting with EC do not find them 
attractive and almost none progress to daily vaping [127]. This contrasts with the fact 
that about half of adolescents who experiment with cigarettes progress to daily smoking 
[128].    
 
In addition to mechanical characteristics of EC and user puffing behaviour discussed in 
previous sections, the composition of the chemicals used to produce the vapour, 
typically vegetable glycerol and/or propylene glycol (PG), may also influence nicotine 
delivery. E-liquid with a mix of vegetable glycerol/PG was associated with better nicotine 
delivery than a vegetable glycerol-only e-liquid with the same concentration of nicotine 
[129]. The presumed effect is that PG vaporises at a faster rate than vegetable glycerol 
when heated in the EC and so is able to carry more nicotine to the user. 
 
If EC continue to improve in the speed of nicotine delivery, they are likely to appeal to 
more smokers, making the switch from smoking to vaping easier. It may be important in 
this context to note that if the smoking-associated risk is removed, nicotine use by itself, 
outside pregnancy, carries little health risk and in fact conveys some benefits.  
 
Table 8: Studies examining nicotine intake in vapers 
 
Study Participants EC Device Methods Results 
Vansickel 
et al 2012 
[119] 
20 
smokers 
naïve to 
EC 
Vapor King 
(cigalike), 
18mg/ml nicotine 
Overnight abstinence, 
baseline blood sample, 
after 5 mins 10 puffs, 
30 sec inter-puff 
interval, 5 mins after 
last puff blood sample. 
Repeated 5x, 30 mins 
in between  
At end of last 
puffing bout 
plasma nicotine  
increased from  
2.2 ng/ml at 
baseline to 7.4 
ng/ml. 
 
Vansickel 
& 
Eissenberg 
2012 [121] 
8 vapers 
using EC 
for 
average 
of 12 
months 
Own EC 
1 used 9 mg/ml 
6 used 18 mg/ml 
1 used 24 mg/ml 
 
Overnight abstinence,  
Baseline blood, after 5 
mins 10 EC puffs at 30 
sec intervals, 5 and 15 
mins after first puff 
blood sample, 60 min 
ad-lib vaping 
Increase in 
plasma nicotine 
from 2.0 ng/ml to 
10.3 ng/ml in 5 
mins. Cmax = 
16.3 ng/ml at end 
of ad lib period 
Yan & 
D’Ruiz 
2014 [129] 
 
23 
smokers  
4 types of Blu 
(cigalike) EC 
(1.6% to 2.4%) 
Marlboro cigarette 
Randomised 6 sessions  
7-days get used to EC,  
36 h abstinence. EC = 
50x5 sec puffs, 30 sec 
During controlled 
puffing Cmax 
(ng/ml): EC 10.3 
to 18.9; cig 15.8  
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Study Participants EC Device Methods Results 
 (cig) 
 
intervals. Cig ad lib puff 
duration at 30 sec 
intervals. Then ad lib 
use for 60 mins. Blood: 
10 mins pre, 5, 10, 15, 
20, 25, 30, 45, 60, 75, 
90 mins post start of 
controlled puffing. 
Tmax: 30mins for 
EC and 5 mins for 
cig 
During ad lib use 
-Cmax (ng/ml): 
EC 13.7 to 22.42; 
cig 29.3 
Vansickel 
et al 2010 
[118] 
32 
smokers) 
Own brand cig 
NJOY EC (18mg) 
Crown 7 EC 
(16mg) 
Sham (unlit cig) 
EC were cigalike 
Randomised crossover, 
overnight abstinence.  
Baseline blood, EC – 
10 puffs at 30 sec 
intervals, blood at 5, 15, 
30, 45, 60 mins  
Only cig 
produced 
significant rise in 
nicotine (18.8 
ng/ml at 5 mins) 
Van Staden 
et al 2013 
[113] 
13 
smokers  
Twisp eGo 
(18mg/ml 
nicotine) 
Provided with EC and 
asked to use this and 
stop smoking for two 
weeks 
Cotinine ng/ml 
Baseline: 287, at 
2 weeks 97 
(p=0.0011) 
Spindle et 
al 2015 
[120] 
13 vapers 
> 3 
months, 
e-liquid 
≥12mg/ml  
Own EC (all tank 
systems) 
1 x 12 mg/ml 
3 x 18 mg/ml 
9 x 24 mg/ml 
Overnight abstinence,  
two sessions. 
Baseline blood, EC – 
10 puffs at 30 sec 
interval. Blood at 5 and 
15 min.  
Plasma nicotine 
at Baseline: 2.4 
ng/ml 
5 mins: 19.2 
ng/ml 
10 mins: 10.2 
ng/ml 
Bullen et al 
2010 [117] 
8 
smokers 
Ruyan V8 
(cigalike) 16mg/ml 
(puff for 5 mins) 
Inhalator 10mg 
(puff for 20 mins) 
Own brand cig 
(puff for 5 mins) 
Randomised crossover, 
overnight abstinence. 
Baseline blood, product 
use, blood at 5, 10, 15, 
30, and 60 mins. 
 
Cmax (ng/nl): 
EC=1.3; Inh=2.1; 
Cig=13.4 
Tmax (mins): 
EC=19.6; 
Inh=32.0; 
Cig=14.3 
Flouris et 
al 2013 
[130] 
15 
smokers 
Giant (cigalike) 
11mg/ml  
Smoked 2 cigs, puffed 
EC to match smoking. 
Cotinine immediately 
and 1 h after puffing  
No difference 
between products 
Capon-
netto et al 
2013 [40] 
Sample 
size not 
stated 
Categoria 
(cigalike) 7.2mg 
for 12 weeks  
 
7.2mg/5.4mg for 
12 weeks 
RCT – 12 weeks of EC 
use 
Salivary cotinine  
6 weeks: 42 
ng/ml; 12 weeks: 
91 ng/ml 
6 weeks: 68 
ng/ml; 12 weeks: 
70 ng/ml 
Etter & 
Bullen 
2011 [110] 
30 vapers 
Mean EC 
use 94 
days 
Own brand EC 
Mean nicotine 
content 18mg/ml 
Ad libitum use Salivary cotinine 
322 ng/ml  
Dawkins & 
Corcoran 
2014 [114] 
14 
vapers, 
7 dual 
users, 
Skycig (cigalike) 
18mg/ml 
10 puffs in 5 mins, then 
1 hour ad lib 
After 10 mins: 
0.74 – 6.77 ng/ml 
After ad lib: 4.35-
25.6 ng/ml 
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Study Participants EC Device Methods Results 
Used EC 
for 4.7 
months 
Nides et al 
2014 [116] 
29 
smokers, 
55% used 
EC in 
past 
NJOY®King Bold 
(cigalike) 26mg  
EC ad lib 1 week, 12 h 
abstinence. 2x10 puffs 
(30 sec inter-puff 
interval) 60 mins apart 
Blood before and 5, 10, 
15, 30 minutes after  
N=16 had no 
baseline plasma 
nicotine  
Rise 5 min after 
first puffs: 3.5 
ng/ml; after 
second puffs: 5.1 
ng/ml  
Norton et 
al 2014 
[112] 
16 
smokers  
Smoke 51 TRIO 
(cigalike) 11 
mg/ml 
Day 1: own brand, 
saliva sample 
Given EC and stopped 
smoking. Saliva at day 
5. Analysis of 16 who 
abstained from smoking 
for 72 hours 
Significant 
decrease in saliva 
cotinine between 
baseline (338.0 
ng/ml) and day 5 
(178.4 ng/ml), 
p<0.001 
Hecht et al 
2014 [111] 
28 vapers 
(median 9 
months), 
96% daily 
users 
Average nicotine 
12.5 +/- 7.0 mg/ml 
All tank system 
EC 
Measured toxicants, 
carcinogens, nicotine 
and cotinine in urine 
Nicotine: 869 
ng/ml  
Cotinine: 1880 
Smokers normally   
Nicotine: 1380 
ng/ml, cotinine: 
3930 ng/ml  
Hajek et al 
2014 [115] 
40 
smokers,  
Greensmoke 
(cigalike) EC 
(2.4% nicotine) 
 
Overnight abstinence 
Baseline blood, first EC 
use ad-lib 5 mins, blood 
at 5, 10, 15, 20, 30 and 
60 mins. Repeated 
after 4-weeks of ad lib 
use  
Baseline: Cmax: 
4.6, Tmax: 5, 
AUC: 96  
4-weeks: Cmax: 
5.7, Tmax: 5, 
AUC: 142  
Farsalinos 
et al 2014 
[122] 
N=23 
vapers 
(19 
months 
use) 
A: V2 (cigalike) 
 
B: Tank system 
EVIC at 9 watts, 
EVOD  
Same 18mg/ml 
liquid 
Abstained for 8 hrs 
Blood baseline and 
after 10 puffs over 5 
mins, 1 h ad lib, blood 
every 15 mins 
A:5 mins: 4.9 
ng/ml 
1h: 15.8 ng/ml 
 
B: 5 mins: 6.6 
ng/ml 
1h: 23.5 ng/ml 
Oncken et 
al 2015 
[123] 
N=20 
smokers 
given EC 
for 2 
weeks 
Menthol or non-
menthol tank 
system with 
18mg/ml liquid 
Blood baseline, 5 min 
ad lib vaping, blood at 
5,10,15,20,30 min 
At 5 min nicotine 
increased by 4-5 
ng/ml 
 
 
Summary of findings  
The accuracy of labelling of nicotine content currently raises no major concerns. Poorly 
labelled e-liquid and e-cartridges mostly contained less nicotine than declared. EC used 
as intended poses no risk of nicotine poisoning to users. However, e-liquids should be 
in ‘childproof’ packaging. 
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Duration and frequency of puffs and mechanical characteristics of EC play a major role 
in determining nicotine content in vapour. Across the middle range of nicotine levels, in 
machine tests using a standard puffing schedule, nicotine content of e-liquid is related 
to nicotine content in vapour only weakly. EC use releases negligible levels of nicotine 
into ambient air with no identified health risks to bystanders. Use of a cigalike EC can 
increase blood nicotine levels by around 5ng/ml within five minutes of use. This is 
comparable to delivery from oral NRT. Experienced EC users using the tank EC can 
achieve much higher blood nicotine levels over a longer duration, similar to those 
associated with smoking. The speed of nicotine absorption is generally slower than from 
cigarettes but faster than from NRT. 
 
Policy implications  
o General labelling of the strength of e-liquids, along the lines used for example 
indicating coffee strength, provides sufficient guidance to consumers. 
 
o Regulatory interventions should ensure optimal product safety but make sure EC 
are not regulated more strictly than cigarettes and can continue to evolve and 
improve their competitiveness against cigarettes.   
Sfety of electronic cigarettes in the light of new evidence 
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10. Safety of e-cigarettes in the light of new 
evidence 
Introduction 
PHE commissioned a review of EC in 2014, which covered EC safety [131]. The review 
found that the hazard associated with use of EC products currently on the market “is  
likely to be extremely low, and certainly much lower than smoking” and “the health risks 
of passive exposure to electronic cigarette vapour are likely to be extremely low”.  
 
These conclusions tally with a review by an international team of experts, which 
estimated the risks of vaping at less than 5% of the risks of smoking [10] and a  
comprehensive review of relevant literature by another international team which 
concluded that “EC aerosol can contain some of the toxicants present in tobacco 
smoke, but at levels which are much lower. Long-term health effects of EC use are 
unknown but compared with cigarettes, EC are likely to be much less, if at all, harmful to 
users or bystanders” [132]. 
 
Over the past few months, however, several reports have suggested that EC may pose 
more risks than previously thought [133-137].  
 
We were asked to review these studies to see if in the light of this new evidence, the 
conclusions of the PHE 2014 review need to be adjusted. We present below the details 
of these studies together with any additional data that may assist with their 
interpretation.  
 
Aldehydes in vapour from e-cigarettes 
Two recent reports raised a possibility that under certain conditions, EC may release 
high levels of aldehydes. Aldehydes, including formaldehyde, acrolein and 
acetaldehyde, are released in tobacco smoke and contribute to its toxicity. Aldehydes 
are also released with thermal degradation of propylene glycol and glycerol in e-liquids. 
Previous studies detected the presence of aldehydes, especially formaldehyde, in the 
vapour from some EC, but at levels much lower than in cigarette smoke [138]. Across 
brands, EC released 1/50th of the level of formaldehyde released by cigarettes. The 
highest level detected was six times lower than the level in cigarette smoke [138]. 
 
In November 2014, following a press release from Japan [136], major media around the 
world reported variations of a headline: “E-cigarettes contain 10 times the carcinogens 
of regular tobacco”. This was based on a Japanese researcher reporting at a press 
conference that during tests on a number of EC brands, one product was identified 
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which released 10 times more formaldehyde than cigarettes. The press release states 
that the formaldehyde was released when the e-liquid was over-heated. The study has 
not been published yet and so no further details are available, but the two experiments 
described below provide the explanation for this finding. 
 
In January 2015, a similar report was published as a research letter to the New England 
Journal of Medicine (NEJM) [133]. In this study, negligible levels of formaldehyde were 
released at lower EC settings, but when a third generation EC (EC with variable power 
settings) was set to the maximum power and the apparatus was set to take puffs lasting 
3–4 seconds, this generated levels of formaldehyde that, if inhaled in this way 
throughout the day, would exceed formaldehyde levels in cigarette smoke between five 
and 15 times.  
 
The EC was puffed by the puffing machine at a higher power and longer puff duration 
than vapers normally use. It is therefore possible that the e-liquid was overheated to the 
extent that it was releasing novel thermal degradation chemicals. Such overheating can 
happen during vaping when the e-liquid level is low or the power too high for a given EC 
coil or puff duration. Vapers call this phenomenon ‘dry puff’ and it is instantly detected 
due to a distinctive harsh and acrid taste (it is detected by vapers, but not by puffing 
machines) [139]. This poses no danger to either experienced or novice vapers, because 
dry puffs are aversive and are avoided rather than inhaled.  
 
A study has just been published testing the hypothesis that the NEJM report used dry 
puffs [140]. An equivalent EC product was set to the same or normal settings and used 
by seven vapers. The vapers found it usable at normal settings, but all received dry 
puffs and could not use the device at the settings used in the NEJM report [133]. The 
product was then machine tested. At the dry puff setting, formaldehyde was released at 
levels reported in the NEJM letter and the Japanese press release. At normal settings, 
there was no or negligible formaldehyde release.  
 
We are aware of two studies that examined aldehyde levels in vapers. In a cross-
sectional study, vapers had much lower levels of acrolein and crotonaldehyde in urine 
than smokers [111]. The other study, funded by the Medicines and Healthcare products 
Regulatory Agency (MHRA), examined changes in acrolein levels in smokers who 
switched to exclusive EC use and in those who continued to smoke while also using 
EC. As both EC and cigarettes release acrolein, there was a concern that ‘dual users’ 
may increase their acrolein intake compared to smoking only. The results showed a 
substantial decrease in acrolein intake in smokers who switched to EC, but it also found 
a significant decrease in acrolein intake in dual users (ie people that were both smoking 
and vaping). This was because they reduced their smoke intake as indexed by exhaled 
CO levels. Normal vaping generated negligible aldehyde levels [141].  
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Although e-liquid can be heated to a temperature which leads to a release of aldehydes, 
the resulting aerosol is aversive to vapers and so poses no health risk. 
 
Summary  
There is no indication that EC users are exposed to dangerous levels of aldehydes. 
 
Effects of e-cigarette vapour on mice lungs 
A paper published in February 2015 [135] generated worldwide media coverage with 
claims that it linked EC to lung inflammation, lung infection, and even lung cancer.  
 
Groups of mice were put in a small container exposing them to vapour from six EC 
(‘Menthol Bold’ 1.8% nicotine) puffed on a rotating wheel at six puffs per minute for 1.5 
hours, twice daily, over two weeks. The control mice were not exposed to this treatment.  
 
Animals were infected with either streptococcus pneumonia via intranasal instillation 
and killed 24 hours later, or with tissue culture influenza virus and monitored for weight 
loss, mortality, and lung and airways inflammation. Compared to the control group, the 
experimental animals had an increase in pro-inflammatory cytokines, diminished lung 
glutathione levels, higher viral titre, and were more likely to lose weight and die. The 
study identified free radicals in EC vapour as the potential culprit. 
 
There are several problems with the study and with the way its results have been 
interpreted.  
 
EC vapour is inhaled as a replacement for tobacco smoke, but the study attempted no 
comparison of the effects on the lungs from smoke and vapour exposures. This makes 
a meaningful interpretation of the results difficult. A comparison was made, however, of 
the levels of free radicals. Even at the very high vapour density generated by the study 
procedure, the level of free radicals identified in vapour was “several orders of 
magnitude lower than in cigarette smoke”.  
 
In addition to this, the mice in the experimental group were exposed to a much higher 
level of stress than the control group, and stress affects bacterial and viral response. 
Long and repeated containment in the small and crowded smoke chamber emitting an 
overpowering smell is a stressor in itself, but the animals also suffered repeated nicotine 
poisoning. The mice showed an average cotinine concentration of 267ng/ml. Cotinine is 
the primary metabolite of nicotine and in humans the amount of nicotine needed to give 
similar cotinine levels are tolerated by heavy smokers, but highly aversive to non-
smokers, who would be expected to feel sick and vomit at this level of exposure. Mice 
are much more sensitive to nicotine than humans (LD50 in mice is 3mg/kg, in humans 
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6.5–13mg/kg [69]). Accelerated weight loss, reduced immunity and early death in the 
experimental group were much more likely the result of protracted stress and nicotine 
poisoning than the result of exposure to free radicals (which were in any case 1,000 
times lower than from cigarettes).  
 
A similar study from 2015 [134] reported oxidant reactivity (which is linked to free 
radicals) of e-liquid and cytokine release in exposed lung tissue and in mice exposed to 
EC vapour. Again, no comparison with exposure to smoke was reported.  
 
Human studies do not corroborate any of the findings reported here. A case study of 
lipoid pneumonia, which could have been caused by EC flavouring, received worldwide 
attention in 2012 [142] but despite extensive interest in the phenomenon, no further 
cases were published. Adverse effects of vaping are primarily local irritation and dry 
mouth [132]. A study that monitored asthma patients who switched from smoking to 
vaping found significant improvements in symptoms and in respiratory function [143]. 
The recent Cochrane Review found no significant adverse effects associated with EC 
use for up to 1.5 years [39].  
 
Summary 
The mice model has little relevance for estimating human risk and it does not raise any 
new safety concerns. 
 
Particles in e-cigarette vapour 
For completeness we are including information on another recent report which was 
interpreted as showing that EC may be dangerous to bystanders. At an EC Summit 
conference in London in November 2014, Harrison and McFiggans reported on particles 
present in EC vapour. Their presentation was reported in the British Medical Journal 
under the title “E-cigarette vapour could damage health of non-smokers” [137]. 
McFiggans and Harrison requested a retraction of the piece because their findings did 
not concern any health risks. It is the content of the particles rather than their presence 
or size which has health implications [144]. 
 
Impact of media reports that e-cigarettes are dangerous 
Together with previous health scares, the articles reviewed here may be having a 
significant impact on public perception of EC safety. In the US, 82% of responders 
believed that vaping is safer than smoking in 2010, but the figure has shrunk to 51% in 
2014 [65]. A perception that EC pose as much risk as smoking is the most likely 
explanation of the recent decline in adoption of EC by smokers [145].  
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Summary of findings  
Two recent worldwide media headlines asserted that EC use is dangerous. These were 
based on misinterpreted research findings. A high level of formaldehyde was found 
when e-liquid was over-heated to levels unpalatable to EC users, but there is no 
indication that EC users are exposed to dangerous levels of aldehydes; stressed mice 
poisoned with very high levels of nicotine twice daily for two weeks were more likely to 
lose weight and die when exposed to bacteria and viruses, but this has no relevance for 
human EC users. The ongoing negative media campaigns are a plausible explanation 
for the change in the perception of EC safety (see Chapter 8).  
 
None of the studies reviewed above alter the conclusion of Professor Britton’s 2014 
review for PHE. While vaping may not be 100% safe, most of the chemicals causing 
smoking-related disease are absent and the chemicals that are present pose limited 
danger. It had previously been estimated that EC are around 95% safer than smoking 
[10, 146]. This appears to remain a reasonable estimate.  
 
Policy implications  
o There is a need to publicise the current best estimate that using EC is around 95% 
safer than smoking. 
 
o Encouraging smokers who cannot or do not want to stop smoking to switch to EC 
could be adopted as one of the key strategies to reduce smoking related disease 
and death.  
Other health and safety concerns 
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11. Other health and safety concerns 
There have been a number of newspaper reports about the hazards of EC use including 
e-liquid ingestion/poisonings, fires, battery explosions etc [147-149]. In this chapter we 
review available national data on these issues to endeavour to quantify the risk.  
 
Poison reports 
Data on e-liquid exposures in the UK are available from the National Poisons 
Information Service (NPIS)[150]. The NPIS provides information about poisoning to 
NHS staff and publishes data based on enquiries made by phone, using their online 
database TOXBASE, and by consultant referrals. The NPIS report for 2013/14 [150] 
details 204 enquiries related to the liquid content of EC and their refills, most of which 
reported accidental exposure, however 21 enquiries were related to intentional 
overdoses using e-liquids. Most incidences concerned ingestion of the liquid in EC or 
their refills (n=182) although small numbers of inhalation (n=17), eye contact (n=13) and 
skin contact (n=12) enquiries were also reported. The NPIS further reported that the 
number of enquiries about e-liquids has increased since 2007 (Figure 20) broadly 
reflecting the increasing popularity of EC.  
 
A large proportion of exposures to e-liquids were in children under five years old (Figure 
21), a finding that is replicated in a US study on calls to poison centres [151]. However, 
the concentration of events concerning children is not unique to e-liquids. Children 
under five years old appear to be more vulnerable than adults to accidental poisoning in 
general (Figure 22). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
E-cigarettes: an evidence update 
 
82 
Figure 20: Number of telephone enquiries to National Poisons Information Service 
(NPIS) about e-cigarettes over time 
 
 
 
Figure 21: Number of enquiries about e-cigarettes to NPIS by age  
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Figure 22: Age of poisoned patients overall reported in telephone enquiries to NPIS 
2013/4 
 
 
Exposures to poisonous liquid among children are of concern; however they should be 
taken in context. The same report from the NPIS recorded 208 exposures to liquid in 
reed diffusers, 1,168 exposures to pesticides and more than 600 to paracetamol. E-
liquids seem to contribute towards domestic poisoning incidents but regulations, such 
as child safety caps, could limit this risk.  
 
The clinical outcomes of exposures to e-liquids, as detailed in the NPIS report, were 
predominantly either ‘no toxicity’ or ‘mild toxicity’. There were two reported cases of 
‘moderate toxicity’ and one ‘severe’ case that required treatment in an intensive care 
unit. Toxicity symptoms included conjunctivitis, irritation of the oral cavity, anxiety, 
vomiting, hyperventilation and changes in heart rate.  
 
Fire 
A number of news articles report the risk of fire and explosions from EC [147, 149, 152]. 
These reports suggest that faulty or incompatible chargers are the main causes of EC 
related fires along with faults relating to lithium batteries [152]. In order to assess the 
risks of fire we used the two data sources below:  
 
1) In 2014, the BBC made Freedom of Information requests to UK fire services [153] 
and reported that there were 43 recorded call outs for fires related to EC in 2013 and 62 
between 1 January 2014 and 15 November 2014. They added that call outs to EC 
related fires were rising in frequency. This report was based on responses from 43 out 
of 46 fire services in the UK [153, 154] 
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2) The official reporting statistics for the UK [155] do not specifically report EC as a 
cause of fire. There were 2,360 accidental fires between April 2013 and March 2014 
where the source of ignition was “smokers’ materials” causing 80 fatalities and 673 non-
fatal casualties. Additionally, there were 3,700 fires from faulty appliances and electrical 
leads causing 19 fatalities and 820 non-fatal casualties. It is not clear what proportion of 
these were caused by EC. 
 
Regulations covering chargers and quality standards of production could help reduce 
the risk of fire and explosion in EC. An unpublished Department for Business, 
Innovation and Skills (BIS) funded market surveillance exercise in 2013/14 found that 
six out of 17 EC had no instructions for charging, and that eight out of 17 EC did not 
have a charging cut-off device and therefore did not meet the requirements of BS EN 
62133:2013 'Safety requirements for portable sealed secondary cells and batteries for 
use in portable devices'4. It seems likely that the risk of fire and electrical fault is similar 
to other domestic electrical products, indicating that EC should be subject to the same 
guidelines and safety mechanisms.  
 
Summary of findings 
There is a risk of fire from the electrical elements of EC and a risk of poisoning from 
ingestion of e-liquids. These risks appear to be comparable to similar electrical goods 
and potentially poisonous household substances.  
 
Policy implications 
o The risks from fire or poisoning could be controlled through standard regulations for 
similar types of products, such as childproof containers (contained within the TPD 
but which are now emerging as an industry standard) and instructions about the 
importance of using the correct charger. 
 
o Current products should comply with current British Standard operating standards. 
 
o Records of EC incidents could be systematically recorded by fire services.  
 
  
                                            
 
4
 BIS Funded Market Surveillance Exercise 2013/14. The Electrical Safety of Electronic Cigarettes and the Labelling of E-
liquids. Lancashire County Council. Unpublished report. 
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12. International perspectives 
Overview 
Internationally, countries have taken a wide variety of approaches to regulating EC 
[156]. Current approaches range from complete bans on the sale of any EC, to applying 
existing laws on other products to EC (poison, nicotine, and/or tobacco laws), to 
allowing EC to be sold under general consumer product regulations. Similarly, within 
countries, different laws have also been applied at the state/provincial level, along with 
municipal by-laws, extending into areas including taxes on EC, and bans on use in 
places where smoking is banned. Furthermore, several nuances in laws exist, making it 
difficult to make broad statements about the regulations in a given country. This section 
focuses on presenting (1) studies that have compared the use of EC internationally 
across countries using representative samples and comparable methods, (2) a brief 
review of adolescent surveys internationally, and (3) the cases of Australia and Canada, 
two countries that have very similar tobacco control policies to the UK but very different 
policies relating to EC. 
 
Use of e-cigarettes among adults internationally  
Three studies have compared the use of EC internationally: (1) International Tobacco 
Control Project (described in the Methodology section), (2) Eurobarometer study and (3) 
Global Adult Tobacco Survey.  
 
The International Tobacco Control Project compared EC use (use defined as less than 
monthly or more often) among smokers and ex-smokers across 10 countries [157]. 
Gravely et al., 2014 found significant variability in use across countries, but data were 
gathered across different years. Gravely et al., 2014 concluded that the study provided 
evidence of the rapid progression of EC use globally, and that variability was due partly 
to the year the survey was conducted, but also market factors, including different 
regulations on EC. Notably, EC use was highest in Malaysia at 14%, where a ban on 
EC was in place.  
 
Two studies using secondary data from the 2012 Eurobarometer 385 survey have 
examined EC use.  Vardavas, et al., 2014 [158] examined ever use (tried once or twice) 
of EC among smokers, ex-smokers and never smokers aged 15 years and over across 
27 EU countries. The study found wide variation in ever EC use among smokers and 
non-smokers, with ever use varying from 20.3% among smokers, 4.4% among ex-
smokers, and 1.1% among never smokers. Of those who had tried, 69.9% reported 
using EC once or twice, and 21.1% and 9% reported ever using or currently using 
occasionally or regularly (use or used regularly or occasionally). It is important to note 
that the question asked about ever using or currently using occasionally or regularly, 
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and thus would overestimate actual current use. Overall, being a smoker was the 
strongest predictor of ever using an EC, younger age was also predictive. Respondents 
who were uncertain about the harmfulness of EC were less likely to have tried an EC.  
Among current smokers, those who had a made a quit attempt in the past year were 
most likely to have ever used EC, along with heavier smokers. With regards to use as a 
smoking cessation aid, 7.1% of smokers who had ever made a quit attempt reported 
having used EC, compared to 65.7% who used no help, 22.5% who used nicotine 
replacement therapy, and 7.3% who received behavioural counselling. Geographical 
differences in EC use noted by the authors included higher ever use in Northern and 
Eastern Europe compared to Western Europe. The study did not go into detail on 
occasional or regular users of EC because the numbers were too low for any detailed 
analyses.  
 
A 2012 study using the same Eurobarometer 385 survey data gave further detail on 
ever having used or currently using EC occasionally or regularly among smokers and 
non-smokers [63]. The study found that regular/occasional use was highest in Denmark 
at 4.2% and lowest in Lithuania and Portugal at 0.6%, and 2.5% in the UK [63]. 
 
The Global Adult Tobacco Survey [159] published findings on EC use in Indonesia 
(2011), Malaysia (2011), Qatar (2013) and Greece (2013) among smokers and non-
smokers, the first countries with available data. Of those respondents who were aware 
of EC, they asked, “Do you currently use e-cigarettes on a daily basis, less than daily, or 
not at all?” and considered  those who said they used ‘less than daily’ or ‘daily’ to be 
current EC users.  
 
Overall, awareness of EC was highest in Greece (88.5%), followed by Qatar (49%), 
Malaysia (21%), and Indonesia (10.9%). Use of EC among smokers was highest in 
Malaysia (10.4%), followed by Qatar (7.6%), Indonesia (4.2%) and Greece (3.4%). Use 
of EC among non-smokers was highest in Greece (1.3%), followed by the other three 
countries, Malaysia (0.4%), Indonesia (0.4%) and Qatar (0.4%). Similar to findings from 
the ITC Project, these numbers are likely influenced by timing of the survey, due to the 
rapid progression of use of EC globally, and other market factors. Together with the 
findings from Gravely et al., 2014 [157] they show the rapid global progression of EC 
use across both high income and lower middle income countries. 
 
Use of e-cigarettes among youth internationally  
Whilst there are very few international or European studies which use consistent 
methodology, there is a rapidly growing body of research on the prevalence of EC use 
in young people at the country level, as well as reviews in this area [eg [160]]. However, 
much of this literature on EC use among adolescents is incomparable because of 
inconsistent measurements of use (confusing ever use, trial, current use), and different 
age ranges involved. In addition, many of the studies have been poorly reported. For 
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example, much has been made of the increase in EC observed in the US using the 
cross-sectional Centers for Disease Control & Prevention (CDC) National Youth 
Tobacco Surveys [161-163].These reports and press coverage have been heavily 
criticised [164-166]. The most important feature of the NYTS data was the fall in 
smoking prevalence over the same period (as observed in the UK, France [167] and 
elsewhere). 
 
The CDC findings indicated that past 30-day use of EC increased among middle and 
high school students. For example, the 2014 data indicated that among high school 
students use increased from 4.5% to 13.4% between 2013 and 2014. Among middle 
school students, current EC use increased from 1.1% in 2013 to 3.9% in 2014. 
However, cigarette smoking had continued to decline during this period (high school 
students: 15.8% to 9.2%; middle school students: 4.7 % to 2.5%) such that smoking 
was at a 22-year low in the US. These findings strongly suggest that EC use is not 
encouraging uptake of cigarette smoking.  
 
Whilst most of the recent studies examining youth EC use emanated from North 
America, the common pattern emerging worldwide is of a very high awareness of EC 
and an increase in trial of these products among young people [168-178]. Nevertheless, 
estimates of prevalence of current use of EC vary widely with the highest being reported 
in Poland at around 30% [174]  and Hawaii (29% tried, 18% current) [178]. Most other 
estimates indicate that a very small minority of youth, less than 3%, currently or recently 
used EC. Whilst EC experimentation is increasing, regular or current use of EC appears 
to be largely concentrated in those already smoking conventional cigarettes. The most 
recent Europe-wide data indicated that 1.1% of never-smokers aged 15 and above had 
ever tried an EC [158]. Yet little research has focused on how EC are being used 
among young people, with limited qualitative research studies in this area [179, 180]. 
Other findings relate to the influence of parents who smoke on EC experimentation in 
youth [eg [170] and associations between EC experimentation and other substance use 
[eg [170, 181]. Several studies have also found an association between EC use and 
openness to cigarette smoking [eg [182] or intentions to smoke cigarettes [eg [168]. 
 
The cases of Australia and Canada 
Australia has applied existing laws on poisons, therapeutic goods, and tobacco 
products to EC. Very broadly speaking, the current laws in Australia have resulted in a 
ban on the sale and importation of EC with nicotine (although there is a mechanism for 
legal import as an unapproved medicine with a doctor’s prescription). There are no 
national level prevalence data on EC use in Australia available at this time. One study 
comparing trends in awareness, trial, and use of EC among nationally representative 
samples of smokers and ex-smokers (use defined as less than monthly or more often) 
in Australia and the UK in 2010 and 2013 found reported EC use in Australia in 2013 at 
6.6% and use in the UK at 18.8% [183]. Although the use of EC was found to be 
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significantly lower in Australia than in the UK in 2013, the use of EC increased at the 
same rate in Australia and the UK between 2010 and 2013 [183].   
 
Canada took a similar approach to regulating EC as Australia by prohibiting the sale of 
EC with nicotine through existing laws. However, a recent House of Commons report 
stated that the current regulatory approach was not working to restrict access to EC with 
nicotine [184]. Canada has now put forward recommendations to develop a new 
legislative framework for EC that would most likely allow the sale of EC with nicotine 
[184]. There has been only one population-level survey of EC use in Canada. The 2013 
Canadian Tobacco, Alcohol and Drugs Survey (CTADS) of Canadians 15 years and 
older found that 9% had ever tried an EC, with trial being higher among young people 
aged 15–19 years at 20% [185]. Use in the past 30 days was lower at 2%, with past 30 
day use being higher among young people aged 15–19 years at 3%. Of those who tried 
an EC, 55% stated the EC did not contain nicotine, while 26% reported it did contain 
nicotine, with 19% reporting uncertainty. Whether the EC they tried contained nicotine is 
uncertain given (1) the ban on the sale of EC with nicotine, and (2) reports that many 
EC sold and bought in Canada are labelled as not containing nicotine but actually 
contain nicotine [184]. Although it is difficult to make comparisons due to different 
survey methods and questions, the percentage of young people (15–19 years) who 
have tried EC in Canada (20%) is roughly similar to the percentage who have tried EC 
in GB in 2014 (reported at 8%, 15%, 18%, and 19%, for ages 15 to 18, respectively). 
 
Summary of findings 
Although EC use may be lower in countries with more restrictions, these restrictions 
have not prevented EC use. Overall, use is highest among current smokers, with low 
numbers of non-smokers reporting ever use. Current use of EC in other countries is 
associated with being a smoker or ex-smoker, similar to the findings in the UK. EC use 
is frequently misreported, with experimentation presented as regular use. Increases in 
youth EC trial and use are associated with decreases in smoking prevalence in all 
countries, with the exception of one study from Poland. 
 
Policy implications 
o Future research should continue to monitor and evaluate whether different EC 
policies across countries are related to EC use and to smoking cessation and 
smoking prevalence. 
 
o Consistent and agreed measures of trial, occasional and regular EC use among 
youth and adults are urgently needed to aid comparability. 
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Appendices 
APPENDIX A: PRISM Flow Diagram5 
 
 
  
                                            
 
5
 Please note that we did not carry out a full systematic review for this report but followed systematic review methods. We 
assessed 94 papers and 9 additional reports included those that were relevant to our objective of describing the use of e-
cigarettes and how they impact smoking behaviour, with a particular focus on the UK.  
 
Records identified through 
database searching 
(n = 3459 ) 
Additional records identified 
through other sources 
(n = 1) 
Records after duplicates removed 
(n =3453) 
Records screened by 
title 
(n =798) 
Records excluded by 
title 
(n =2655) 
Records screened by 
abstract 
(n = 446) 
Records excluded by 
abstract 
(n = 336 (+16 foreign 
language or abst 
missing)) 
Full-text articles 
assessed for eligibility 
(n =94 ) 
Additional reports, news 
stories etc 
(n = 10) 
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APPENDIX B: Measures of e-cigarette use 
Measures of EC use in studies referenced, in most cases respondents were only asked 
about EC use if they first answered yes to ever trying an EC/had heard of EC. 
 
Surveys 
These questions in all surveys below may have been slightly altered from year to year as the 
EC market evolved and awareness grew. 
 
Smoking Toolkit Study (STS) 
The following four questions are used to assess current use of e-cigarettes: (if already 
responded they are cutting down) 
 
Q632e37. Which, if any, of the following are you currently using to help you cut down 
the amount you smoke? 
Nicotine gum 
Nicotine replacement lozenges\tablets 
Nicotine replacement inhaler 
Nicotine replacement nasal spray 
Nicotine patch 
Electronic cigarette 
Nicotine mouthspray 
Other (specify) 
 
Q632e1. Do you regularly use any of the following in situations when you are not 
allowed to smoke? 
Nicotine gum 
Nicotine lozenge 
Nicotine patch 
Nicotine inhaler\inhalator 
Another nicotine product 
Electronic cigarette 
Nicotine mouthspray 
Other (specify) 
 
NEWW53a. Can I check, are you using any of the following either to help you stop 
smoking, to help you cut down or for any other reason at all? 
 
Nicotine gum 
Nicotine lozenge 
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Nicotine patch 
Nicotine inhaler\inhalator 
Another nicotine product 
Electronic cigarette 
Nicotine mouthspray 
Other (specify) 
 
QIMW86_1. Can I check, are you using any of the following? 
PROBE FULLY: Which others? PROBE UNTIL RESPONDENT SAYS ‘NO OTHERS’ 
PLEASE TYPE IN OTHER ANSWERS CAREFULLY AND USE CAPITAL LETTERS 
Nicotine gum 
Nicotine lozenge 
Nicotine patch 
Nicotine inhaler\inhalator 
Another nicotine product 
Electronic cigarette 
Nicotine mouthspray 
Other (specify) 
 
ASH Smokefree GB adult survey 
Which of the following statements BEST applies to you? 
o I have heard of e-cigarettes and have never tried them 
o I have heard of e-cigarettes but have never tried them 
o I have tried e-cigarettes but do not use them (anymore) 
o I have tried e-cigarettes and still use them 
o Don’t know 
 
The fourth option constitutes ‘current use’ 
 
ASH Smokefree GB youth survey 
An e-cigarette is a tube that looks like a normal cigarette, has a glowing tip and puffs a 
vaour that looks like smoke but unlike normal cigarettes, they don’t burn tobacco.  
Have you ever heard of e-cigarettes? 
o Yes, I have 
o No, I haven’t 
 
All those who have heard of e-cigarettes:  Which one of the following is closest to 
describing your experience of e-cigarettes? 
o I have never used them 
o I have tried them once or twice 
o I use them sometimes (more than once a month) 
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o I use them often (more than once a week) 
o Don’t want to say 
 
Internet cohort survey 
Have you ever heard of electronic cigarettes or e-cigarettes? These are electronic 
devices that contain nicotine in a vapour and are designed to look like cigarettes, but 
contain no tobacco. 
Yes/No/Don’t know 
 
If Yes, Have you ever tried an electronic cigarettes? 
Yes/No/Don’t know 
 
If Yes, How often if at all, do you currently use an electronic cigarette? (PLEASE 
SELECT ONE OPTION) 
1. Daily 
2. Less than daily, but at least once a week 
3. Less than weekly, but at least once a month 
4. Less than monthly 
5. Not at all 
6. Don’t know   
 
Other studies 
Amrock et al., 2015 (US) 
Which of the following tobacco products have you ever tried, even just one time?” to 
which they could select, “electronic cigarettes or e-cigarettes, such as Ruyan or NJOY” 
alongside other tobacco products. A related question asked if students used e-
cigarettes on at least one of the past 30 days. 
 
Biener & Hargraves, 2014 (US) 
At baseline, three questions were asked about e-cigarettes: whether the respondent 
had “ever heard of electronic cigarettes, also known as e-cigarettes”; if so, whether 
he/she had ever used an e-cigarette even one time, and if so, on how many of the past 
30 days the respondent had used an e-cigarette. To assess how intensively and for how 
long the respondent had used e-cigarettes during the period between interviews, the 
follow-up interviews included questions to describe e-cigarette usage. Those who were 
not aware of e-cigarettes at baseline were asked if they had heard of them at follow-up. 
Those who had not tried e-cigarettes at baseline were asked if they had done so by 
follow-up. All respondents who reported ever trying them by follow-up were asked 
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whether they currently used e-cigarettes every day, some days or not at all. If not at all, 
they were asked if they ever used e-cigarettes “fairly regularly.” If not, whether they had 
used only once or twice or more often than that. All who had used more than once or 
twice, were asked a series of questions about their patterns of use: for how long they 
had used e-cigarettes (less than a month, 1–6 months, more than 6 months); whether 
they had ever used e-cigarettes daily for at least one week; if so for how long they had 
used e-cigarettes daily. From these variables, a 3-level measure of intensity of e-
cigarette usage was computed: 3 = intensive (used daily for at least 1 month); 2 = 
intermittent (more than once or twice but not daily for a month or more); 1 = non-use or 
at most once or twice. 
 
Borderud et al., 2014 (US) 
Patients were asked if they had used E-cigarettes within the past 30 days, with the 
response options being yes or no. 
 
Brose et al, 2015 and Hitchman et al., 2015 (GB) 
How often, if at all, do you currently use an electronic cigarette? [Asked of respondents 
who had ever heard of e-cigarettes and had ever tried one.]  
1. Daily 
2. Less than daily, but at least once a week 
3. Less than weekly, but at least once a month 
4. Less than monthly 
5. Not at all 
6. Don't know 
 
What electronic cigarette equipment do you currently use the most?  
1. A disposable electronic cigarette (non-rechargeable) 
2. A commercial electronic cigarette kit which is refillable with pre-filled cartridges 
3. A commercial electronic cigarette kit which is refillable with liquids   
4. A modular system (I use my own combination of separate devices: batteries, atomizers, 
etc.) 
5. Don’t know 
 
Brown et al., 2014 (England) 
Which, if any, of the following did you try to help you stop smoking during the most 
recent serious quit attempt?  
1. E-cigarettes 
2. NRT bought over-the-counter 
3. No aid 
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Canadian Tobacco, Alcohol and Drugs Survey 2013 (CTADS) 
Trial 
Have you ever tried an electronic cigarette, also known as an e-cigarette? 
1. Yes 
2. No 
3. Refused 
4. Don’t know 
 
Last 30 day use 
In the past 30 days did you use an electronic cigarette, also known as an e-cigarette? 
1. Yes 
2. No 
3. Refused 
4. Don’t know 
 
CDC/NYTS and Dutra and Glantz 
During the past 30 days, on how many days did you use electronic cigarettes or e-
cigarettes such as Blu, 21st Century Smoke, or NJOY? 
 
Gravely et al., 2014 (Republic of Korea, US, UK, Canada, Australia, and Malaysia); 
Yong et al., 2014 (UK and Australia)  
How often, if at all, do you currently use an electronic cigarette? (dichotomised into 
current use and non-current by combining any use responses vs. not at all) 
1. Daily, Less than daily but at least once a week 
2. Less than weekly but at least once a month 
3. Less than monthly 
4. Not at all 
 
Gravely et al., 2014 (Netherlands) 
How often do you currently use an electronic cigarette? (dichotomised into current use 
and non-current by combining any use responses vs. have you stopped altogether) 
1. Daily 
2. Less than daily, but at least once a week 
3. Less than weekly, but at least once a month 
4. Less than monthly versus, or 
5. Have you stopped altogether? 
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Gravely et al., 2014 (China) 
Are you currently using an electronic cigarette at least weekly? (Yes vs. No) 
1. Yes 
2. No 
 
Hughes et al., 2014 (Trading Standards NW Study) 
“Have you ever bought or tried electronic cigarettes?” 
 
Hummel et al., 2014 (Netherlands)  
Respondents who had ever tried e-cigarettes were asked how often they currently used 
an e-cigarette (daily, at least once a week, at least once a month, less than monthly, or 
stopped altogether 
 
Lee et al., 2014 (US) 
E-cigarette use questions were:  
 
Have you ever used e-cigarettes? 
1. yes 
2. no 
Have you used e-cigarettes in the past 30 days? 
1. yes 
2. no 
 
Moore et al., 2014 (Welsh study 10-11 year olds) 
“Have you heard of e-cigarettes before this survey?” 
‘Have you ever used an e-cigarette? with response options of ‘no’, ‘yes, once’ or’ yes, more 
than once’ 
 
Moore et al., 2015 (Welsh study HBSC) 
Asked whether they had ever used an e-cigarette with response options of: 
o I have never used or tried e-cigarettes 
o I have used e-cigarettes on a few occasions (1-5 times); 
o I regularly use e-cigarettes (at least once a month)’. 
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Palipudi et al., 2015 (Global Adult Tobacco Survey) 
“Do you currently use e-cigarettes on a  
1. Daily basis,  
2. Less than daily,  
3. Or, not at all?” 
 
Pearson et al., 2014 (US) 
Participants were asked which methods they had used to quit in the past 3 months and 
were presented a list of common quit methods. Participants were considered e-cigarette 
users if they selected “e-cigarettes” in response to this question or if they entered terms 
like “vapors,” “vaping,” “vape,” or “ecigs” in the “other quit methods” open-ended 
response option. 
 
Pepper et al., 2014 (US) 
Have you ever used an e-cigarette, even one puff? 
Do you now use e-cigarettes every day, some days, or not at all? 
 
Richardson et al., 2014 (US) 
Please indicate whether you have ever heard of these products, if you have ever tried 
them and if you have ever purchased them. Products included ENDS; dissolvables; 
chew, dip, or snuff (assessed in 1 question); and snus, each presented with brand 
names to increase validity of responses. Respondents could choose multiple options 
from the following choices: (1) heard of; (2) tried; (3) purchased; (4) never heard of, 
tried, or purchased (for those to whom options 1, 2, and 3 were not applicable); (5) 
refused; and (6) don’t know. 
 
Rutten et al., 2014 (US) 
Do you now use e-cigarettes (eg BluCig, NJoy, V2, Red Dragon, etc)? [Picture of three different 
e-cigarettes included] 
1. Every day  
2. Some days 
3. Not at all 
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Schmidt et al., 2014 (US) 
Have you ever used an electronic cigarette, even just one time in your entire life? 
Do you now use electronic cigarettes every day, some days, rarely, or not at all? 
 
Vardavas et al., 2014 (Eurobarometer 27 countries), dichotomised into regularly, 
occasionally, tried once or twice vs. otherwise; Agaku et al., 2014 (Eurobarometer, 25 
countries), dichotomised into regularly or occasionally vs. otherwise;  
Have you ever tried any of the following products? (Electronic cigarettes) 
1. Yes, you use or used it regularly. 
2. Yes, you use or used it occasionally.  
3. Yes, you tried it once or twice. 
4. No. 
5. Don’t Know. 
 
White et al., 2015, New Zealand national youth tobacco use survey in 2012 and 2014 
Ever use: Have you ever tried electronic cigarettes?  
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Appendix C: Narrative summary of studies on nicotine delivery from e-cigarettes 
Early studies 
Two studies, both published in 2010, examined nicotine delivery from cigalike EC. 
 
Bullen et al., 2010 used a cross-over design to compare nicotine delivery of a 16mg/ml 
Ruyan V8 EC with a 0mg/ml EC, a nicotine inhalator (10mg) and a conventional 
cigarette among 8 smokers who abstained from smoking overnight [43]. Participants 
puffed on their cigarettes and EC ad libitum over 5 minutes, and on the inhalator over 
20 minutes. The nicotine containing EC had similar pharmacokinetic parameters to the 
inhalator (Cmax: 1.3 vs. 2.1 ng/ml; Tmax: 19.6 vs. 32.0 mins), and both were out-
performed by a conventional cigarette (Cmax 13.4 ng/ml; Tmax 14.3 mins). 
 
Vansickel et al., 2010 also used a cross-over design and tested nicotine delivery of two 
EC (NJOY EC (18mg) and Crown 7 EC (16mg) and participants own brand 
cigarette[118]. Participants abstained overnight and then took 10 puffs on the EC with a 
30 sec inter-puff interval. Only the conventional cigarette produced a significant rise in 
plasma nicotine, from baseline 2.1 ng/ml (SD 0.32) to a peak at 5 minutes 18.8 ng/ml 
(SD 11.8).  
 
The poor nicotine delivery of these EC was likely to be due to several factors. The EC 
tested were some of the first to market. The EC used in the Bullen 2010 study were 
noted to leak and the vaporising component did not always function. Both of these early 
studies recruited EC naïve smokers, without opportunity to practice using the EC prior 
to experimentation. 
 
There are other factors that are associated with nicotine delivery, which we have 
summarised below. 
 
1) More intensive vaping regimens 
Vansickel et al., examined nicotine delivery associated with the use of Vapor King 
(cigalike EC with 18mg/ml nicotine) in 20 smokers naïve to EC [119]. After overnight 
abstinence, participants used the EC for 5 minutes on a total of six occasions (10 puffs, 
30 sec inter-puff interval) 30 minutes apart. A significant increase in plasma nicotine 
was observed after the fourth bout of puffing, and mean blood nicotine levels had 
increased from 2.2 ng/ml (SD 0.78) at baseline to 7.4 ng/ml (SD 5.1) at the end of the 
last bout of puffing. 
 
2) Experience with EC 
Vansickel & Eissenberg (2012) report nicotine pharmacokinetics in eight vapers who 
had been using EC for average of 11.5 (SD 5.2) months [7]. They used their own EC 
and e-liquid (the majority used an e-liquid with a concentration of 18 mg/ml). 
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Participants attended the laboratory after overnight abstinence and used their EC under 
a standardised vaping regimen (10 puffs with a 30 second inter-puff interval) and then a 
60 minutes period of ad lib vaping. The PK analyses showed a significant increase in 
plasma nicotine from baseline 2.0 ng/ml to 0.3 ng/ml within five minutes of the first puff. 
At the end of the ad-lib vaping period the maximum plasma nicotine concentration was 
16.3 ng/ml. 
 
Dawkins and Corcoran (2014) examined nicotine delivery associated with the used of 
the Skycig 18 mg Crown tobacco bold cartridges in 14 vapers, who had been vaping for 
almost 5 months on average[6]. Using a similar methodology to Vansickel & Eissenberg 
(2012), the analysis of plasma nicotine from the seven participants that provided a full 
blood set, showed that levels had increased from 0.74 to 6.77 ng/ml in 10 minutes. 
However there was individual variation (2.5 ng/ml to 13.4 ng/ml). After an hour of ad lib 
use the maximum nicotine concentration reached was 13.91 ng/ml, again with a wide 
range of levels observed between individuals (4.35-25.6 ng/ml). 
 
Spindle et al., 2015 studied 13 experienced EC users (> 3 months, with the majority 
9/13 using e-liquid strength of 24mg/ml and all using tank systems)[120]. Taking 10 
puffs over 5 minutes resulted in an increase in mean blood nicotine levels from 2.4 
ng/ml baseline to 19.2 ng/ml at 5 minutes. 
 
Practice in EC use also results in a modest increase in blood nicotine levels. Hajek et 
al., 2014 tested Greensmoke EC (a cigalike EC with 2.4% nicotine) in 40 smokers, 
naïve to EC[115]. Participants abstained from any nicotine use overnight and after a 
baseline blood sample was collected used the EC, ad lib, for 5 minutes. This procedure 
was undertaken twice, on first use and then again after 4 weeks of use. The maximum 
plasma concentrations increased from 4.6 ng/ml (range 0.9-9.0) to 5.7 ng/ml (range 1.9-
11.0), although this increase was not significant. The area under the curve (AUC), 
however, did show a significant increase, from 96 (range 12-198) to 142 (range 56-234). 
The time to maximum plasma concentration (5 minutes) did not change. 
 
Nides et al., 2014 provided EC to participants (29 smokers, mean cigarette consumption 
of 20 cpd, and of 55% of whom had used EC in past) but also allowed them to practice 
using the EC (NJOY®King Bold, a cigalike EC, with 26mg nicotine) for a week prior to 
undertaking a PK analysis [116]. Participants (who abstained from all nicotine products 
for at least 12 hours) then were asked to use EC (10 puffs with a 30 second inter-puff 
interval) on two occasions 60 minutes apart. Pharmacokinetic (PK) analyses were 
undertaken in 16 participants who had no detectable plasma nicotine at baseline. The 
mean rise in blood nicotine was 3.5 ng/ml (range 0.8-8.5 ng/ml) at 5 minutes after the 
first round of puffing and 5.1 ng/ml (range 1.1 – 7.1 ng/ml) at 10 minutes after the 
second. 
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3) Nicotine concentration and chemical composition of e-liquid 
Yan & D’Ruiz (2014) examined nicotine delivery from Blu cigalike EC with differing 
levels of nicotine (2.4% and 1.6%), glycerin/propylene glycol (75% glycerin and 50% 
glycerin/20% propylene glycol), and flavours (classic tobacco and menthol)[129]. 
Participants (23 smokers) were randomized to 5 different EC conditions and smoking a 
regular cigarette in a cross over design. They were given 7 days to familiarize with EC 
use, and then abstain from all nicotine products for 36 hours prior to test days. On test 
days participants were asked to take 50 x 5 second puffs on EC at 30 sec intervals (in 
the cigarette arm they smoked 1 cigarette with usual puff duration at 30 sec intervals). 
After the controlled puffing testing ppts were allowed 60 minutes of ad lib use. 
 
Peak plasma nicotine concentrations were reached sooner for cigarettes (5 minutes) 
than for EC (30 minutes). During the 30 minutes controlled puffing phase, within EC 
conditions the highest Cmax was seen with the 2.4% nicotine, 50% glycerin/20% PG 
(18.09 ng/ml, SD=6.47 ng/ml). The lowest Cmax was observed in the 1.6% nicotine, 
75% glycerine (10.34 ng/ml SD=3.70 ng/ml). The Cmax associated with smoking one 
conventional cigarette was 15.84 ng/ml (SD = 8.64 ng/ml). At the end of the ad lib 
period, the highest Cmax was seen with the conventional cigarette (29.23 ng/ml SD = 
10.86 ng/ml), followed by the 2.4% nicotine, 50% glycerin/20% PG EC (22.42 ng/ml; SD 
= 7.65ng/ml). The glycerine/PG mix resulted in better nicotine delivery than the 75% 
glycerine solution, which was confirmed in the bench top tests that measured nicotine 
content in vapour using the Canadian Intense regimen. The high nicotine content in 
vapour is a likely consequence of the lower boiling point of PG (187.6 degrees Celsius) 
compared with glycerine (290 degrees Celsius). 
 
4) Type of EC device 
Although many vapers start off with using a cigalike EC experienced vapers are more 
likely to be using tank systems or variable power EC. One of the reasons for this 
observation is that the tank systems and variable power ECs deliver nicotine more 
nicotine to the user. 
 
Farsalinos et al., (2014) examined plasma nicotine levels in experienced vapers (n=23) 
who used a cigalike (V2 with cartomiser) and a new generation (EVIC set at 9 watts with 
EVOD atomizer) EC with standardized flavour and nicotine concentration (18mg/ml) in a 
cross-over design[129]. Participants’ abstained from EC use for at least 8 hours before 
completing a bout of 10 puffs over 5 minutes followed by one hour of ad lib use. Use of 
the cigalike EC was associated with an increase in blood nicotine from 2.80 ng/ml at 
baseline, to 4.87 ng/ml at 5 minutes and 15.75 ng/ml at the end of ad lib use. 
Significantly greater increases were observed with use of the new generation EC from 
2.46 ng/ml to 6.59 ng/ml to 23.47 ng/ml at baseline, 5 minutes and at the end of the ad 
lib period. 
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Oncken et al., (2015) also examined nicotine delivery in a tank system EC (Joye eGo-C 
with 18 mg/ml nicotine e-liquid) in 20 smokers who were asked to use an EC for two 
weeks[123]. Participants were asked to use the EC for 5 minutes ad lib in two laboratory 
sessions where blood samples were taken for PK analysis. Blood nicotine 
concentrations increased, significantly, by 4 ng/ml (Cmax 8.2 ng/ml) at the first session 
and 5.1 ng/ml (Cmax 9.3 ng/ml) at the second session. These levels were reached at 
five minutes. 
 
Studies that examine cotinine as a measure of nicotine replacement in vapers 
We found eight studies that reported on cotinine in urine, blood or saliva as a marker of 
nicotine exposure in people using EC. 
 
In an RCT of nicotine containing EC versus placebo Caponnetto and colleagues (2013) 
measured salivary cotinine in participants who had stopped smoking cigarettes, but 
were still vaping EC (Categoria 7.5mg/ml)[40]. After 12 weeks of use the mean salivary 
cotinine concentration was 67.8 ng/ml, which is at the lower end of what is typically 
observed in smokers (eg 66.9-283.7 ng/ml). 
 
In a study that randomised 48 smokers unwilling to quit to one of two tank system EC 
(18mg/ml nicotine) or to continue to smoke found that at 8 month follow-up mean 
salivary cotinine did not significantly differ between those who had stopped smoking but 
were vaping (428.27 ng/ml), achieved a ≥50% reduction in cigarette consumption 
(356.49 ng/ml) and those who continued to smoke (545.23 ng/ml, SD = 46.32)[41]. 
 
Van Staden et al., (2013) examined the change in serum cotinine in 13 smokers who 
were asked to stop smoking and instead use a Twisp eGo (18mg/ml nicotine) tank 
system EC for two weeks[113]. There was a significant decrease in cotinine from 
baseline 287.25 ± 136.05 to two weeks 97.01 ± 80.91 ng/ml suggesting that the EC 
used did not provide as much nicotine as participants usual cigarettes. 
 
Norton et al., (2014) observed a similar result in 16 abstinent smokers who used a 
cigalike EC (11 mg/ml) for five days, finding a significant decrease in saliva cotinine 
between baseline (338.0 ng/ml) and day five (178.4 ng/ml)[112]. 
 
Flouris et al., (2013) measured serum cotinine in 15 smokers, who had abstained 
overnight, after smoking two of their usual cigarettes over 30 minutes and after 30 
minutes of vaping a cigalike EC (Giant, 11mg/ml)[130]. EC and cigarettes produced 
similar effects on serum cotinine levels (60.6 ± 34.3 versus 61.3 ± 36.6 ng/ml). However 
measurement of cotinine would not give an accurate indicator of exposure in an acute 
study such as this. 
 
E-cigarettes: an evidence update 
 
111 
Experienced vapers, using their own devices, however obtain much better nicotine 
substitution. Etter and Bullen (2011) measured salivary cotinine concentrations in 30 
vapers who had been using EC for approximately 3 months on average and no longer 
smoking[9]. The mean nicotine content of e-liquid was 18mg/ml. Mean salivary cotinine 
was found to be 322 ng/ml indicating a high level of nicotine replacement via EC. 
 
Similarly Etter (2014) found mean cotinine levels of 374 ng/ml (95% CI: 318-429) in 62 
vapers who had not used any other nicotine containing products in the last 5 days [8]. 
 
Hecht et al., 2014 measured nicotine and cotinine in urine of 28 EC users (median use 
of 9 months, using tank system EC with e-liquid containing, on average 12.5 ± 7.0 
mg/ml)[111]. Nicotine and cotinine levels in urine were 869 ng/ml (95% CI: 604-1250) 
and 1880 ng/ml (95% CI: 1420-2480) respectively, although these levels are lower than 
what are typically observed in smokers (eg nicotine 1380 ng/ml 95% CI: 1190-1600 and 
cotinine 3930 ng/ml; 95% CI: 3500-4400). 
